PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

SEC

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [4] :
C12P 21/00, 21/02, C12N 5/00
C07K 7/10, C07H 15/12

A1

(11) International Publication Number: WO 88/03170

(43) International Publication Date: 5 May 1988 (05.05.88)

(21) International Application Number: PCT/US87/02536

(22) International Filing Date: 2 October 1987 (02.10.87)

(31) Priority Application Numbers: PCT/US86/02258
939,206
60,719
101,680

(32) Priority Dates: 24 October 1986 (24.10.86)
8 December 1986 (08.12.86)
10 June 1987 (10.06.87)

516 Fairlawn Avenue, Libertyville, IL 60048 (US).

(74) Agent: GRUBER, Lewis, S.; Marshall, O'Toole, Gerstein, Murray & Bicknell, Two First National Plaza, Suite 2100, Chicago, IL 60603 (US).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

No	références, formules, pages à photocopier, etc	No	classement
1	a complex	1	C07K 13/00 -1
2	P1-12, 27-54, 82-83 Fig 1-10E SURFACTION ASSOC. PROT. (SAP)	2	INF C12N15/12
3	P35, 36, 44-51, Fig 7 fusion - Rec 2 / SAP - CMP-KDO Synthetase / SAP (CKS)	3	INF C12N15/62
4	P35, 36, 44-51, Fig 7	4	INF C12N15/70
5	0-12, 69-93	5	INF. A61K37/02+M
6	0-12, 69-93	6	INF A61K35/42+M
7	0-27, 82-93	7	INF. A61K35/42
8	0-12, 64-66, 82-93	8	INF. C12P21/00E
9	0-17, 52-69, 82-93, [illegible]	9	INF C07K7/10A
10	0-17, 82-93	10	INF C07K7/10A

Modelo 350

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 :
C12P 21/00, 21/02, C12N 5/00
C07K 7/10, C07H 15/12

A1

(11) International Publication Number: WO 88/ 03170

(43) International Publication Date: 5 May 1988 (05.05.88)

(21) International Application Number: PCT/US87/02536

(22) International Filing Date: 2 October 1987 (02.10.87)

(31) Priority Application Numbers: PCT/US86/02258
939,206
60,719
101,680

(32) Priority Dates: 24 October 1986 (24.10.86)
8 December 1986 (08.12.86)
10 June 1987 (10.06.87)
1 October 1987 (01.10.87)

(33) Priority Country: US

(71)(72) Applicants and Inventors: WHITSETT, Jeffrey, A. [US/US]; 5565 Salem Road, Cincinnati, OH 45229 (US). FOX, J., Lawrence [US/US]; 634 Rockland Avenue, Lake Bluff, IL 60044 (US). PILOT-MATIAS, Tami, J. [US/US]; 205 Appley Avenue, Libertyville, IL 60048 (US). MEUTH, Joseph, L. [US/US]; 310 Charlotte, Mundelein, IL 60060 (US). SARIN, Virender, K. [IN/US]; 516 Fairlawn Avenue, Libertyville, IL 60048 (US).

(74) Agent: GRUBER, Lewis, S.; Marshall, O'Toole, Gerstein, Murray & Bicknell, Two First National Plaza, Suite 2100, Chicago, IL 60603 (US).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEINS

(57) Abstract

Novel, isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight, SAP(Val) and SAP(Phe); multimers thereof, and substitution, addition and deletion analogs and fragments thereof. When SAP(Val) and/or SAP(Phe) is combined with lipids, its surfactant-like property imparts to the combination significant pulmonary biophysical activity. Such a combination results in enhanced adsorption of the lipids with properties similar to that of natural pulmonary surfactant material. SAP(Val) and/or SAP(Phe) in combination with lipids is highly useful for replacing or supplementing natural pulmonary surfactant material for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from hyaline membrane disease, HMD, or other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. A combination of SAP(Val) and/or SAP(Phe) and lipids may be administered as an aerosol spray or in aqueous normal saline with or without calcium chloride for treating or preventing HMD and other surfactant deficiency states. Also disclosed are methods of isolating the SAP(Val) from animal tissue and methods for making SAP(Val) and SAP(Phe) by recombinant DNA techniques and direct peptide synthesis; genomic clones of SAP(Val) and SAP(Phe); expression systems and products for SAP(Val) DNA; and polyclonal and monoclonal antibodies to SAP(Val) and SAP(Phe).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

PULMONARY HYDROPHOBIC SURFACTANT-ASSOCIATED PROTEINS

Background

The present application relates to pulmonary hydrophobic surfaction associated proteins ("SAPs") and methods for the isolation and use thereof. In particular, the present application relates to SAP(Val), methods for isolation thereof and methods for the use thereof.

Hyaline membrane disease ("HMD") is a common disorder of premature infants and is related to diffuse atelectesis, hypoxia and resultant respiratory impairment. More particularly, HMD relates to the lack of vital pulmonary materials necessary for reducing surface tension in the airways of the alveoli. As a result, the alveoli or terminal respiratory sacs of patients suffering from HMD normally collapse. And, because the surface tension at the gas-liquid interface in HMD patients is elevated, their alveoli or terminal respiratory sacs are very difficult to reinflate. Consequently, HMD may be associated with significant morbidity and mortality, especially in premature infants.

Present treatments for HMD employ high concentrations of oxygen, positive pressure and/or mechanical ventilation to maintain adequate oxygenation. Such treatments are complicated by oxygen-

and pressure-related injuries as well as by injuries resulting from the need to mechanically access the airway via endotracheal tubes.

Another approch to treatment of HMD and other syndromes associated with a lack of pulmonary surfactant material involves the use of replacement pulmonary surfactant material. Other syndromes associated with a lack of pulmonary surfactant material include adult respiratory distress syndrome ("ARDS") caused by, for example, trauma, sepsis, smoke inhalation and myocardial infarction. In addition, syndromes associated with a lack of pulmonary surfactant material include any chronic obstructive pulmonary diseases, pneumonia or other conditions resulting in damage to pulmonary type II cells.

Therapy for syndromes associated with a lack of pulmonary surfactant material may include the use of aerosolized or liquid synthetic phospholipid mixtures, natural pulmonary surfactant material and various preparations of surfactant material prepared from animal lung. The surface tension lowering ability of naturally derived preparations is in general better than that of synthetic lipid preparations. Modified bovine surfactants are also proposed for use in such preparations. However, problems with human and animal pulmonary preparations include batch-to-batch variability and possible infection and immunologic risks.

When treating patients for HMD, it is important to employ only the required active substances in order to minimize possible adverse immunologic consequences of therapy. Unfortunately, because the available natural pulmonary surfactant material and preparations are in crude form, they are less specific and are possibly associated with greater immunologic risks.

Natural pulmonary surfactant is a complex material composed primarily of phospholipids and surfactant-associated proteins or apolipoproteins. The phospholipids, mainly phosphatidycholine ("PC"), disaturated phosphatidycholine ("DSPC") and phosphatidylglycerol ("PG"), are of paramount importance for the physiological role of natural pulmonary surfactant material in reducing surface tension in the alveoli. Phospholipids, of which DSPC is the principal component, are synthesized in the endoplasmic reticulum of Type II epithelial cells, packaged into lamellar bodies, then secreted into the alveolar space by an exocytotic process. It is believed that several of the phospholipids are not catabolized and resynthesized, but that they are reutilized, primarily as intact molecules, and that they constitute the major components of the natural pulmonary surfactant material.

With respect to the surfactant-associated proteins or apolipoproteins, there is considerable disagreement as to their identity and utility. Nonetheless, there is an increasing agreement that, in addition to the lung surfactant phospholipids, at least some apolipoproteins are vital for the full biological activity of the natural pulmonary surfactant material in reducing surface tension in the alveoli.

Surfactant-associated proteins or apolipoproteins include both serum- and lung-specific proteins. The major lung specific surfactant-associated protein of M_r=30-40,000 daltons is identified in lung surfactant by King et al., Am. J. Physiol., 244, 788-795 (1973), is a glycoprotein which is rich in glycine and which contains a collagen-like region rich in hydroxyproline. This protein, herein called SAP-35, is synthesized from M_r=28-30,000 dalton translation products which undergo glycosylation, hydroxylation of proline residues and sulfhydryl-dependent cross-linking

to form large oligomers which may be detected in the airway. Proteolytic fragments of SAP-35 are found in protein preparations isolated from lavage of patients with alveolar proteinosis and from other mammalian surfactants migrating as proteins of small molecular weight [Whitsett et al., Pediatr. Res., 19, 501-508 (1985)]. While the glycoprotein SAP-35 binds phospholipids and may confer the structural organization of tubular myelin to surfactant lipids, SAP-35 may not be required for the biophysical activity of surfactants. See King et al., J. Appl. Physiol., 42, 483-491 (1977).

Smaller lung specific surfactant-associated proteins are also identified from a variety of mammalian surfactants. A 10,000-12,000 dalton protein may be present in pulmonary surfactant material [King et al., Am. J. Physiol, 223, 715-726 (1972)]. This protein is now believed to be a fragment of the major glycoprotein SAP-35. Smaller surfactant-associated proteins may be present in alveolar lavage material from a number of species and may have molecular weights of approximately 10,000 daltons in the dog and the rabbit, 10,500-14,000 daltons in the rat, 11,500-16,500 daltons in the pig, and 10,000 daltons in the cow.

The nature of and the relationships among these various smaller surfactant-associated proteins and the larger protein, SAP-35 or its fragments, have not been established. Nevertheless, Suzuki et al., J. Lipid. Res., 23, 53-61 (1982), suggests that a small 15,000 dalton protein in pig alveolar lavage may have a greater affinity for lipid than SAP-35. However, Suzuki et al. does not distinguish this protein from SAP-35 or its fragments and does not demonstrate surfactant properties in a purified state. Rather, Suzuki et al. only suggests that this 15,000 daltons protein is possibly a physiological regulator for the clearance of

alveolar phospholipid. A small SAP protein is reported to be isolated from rat alveolar lavage by isolation methods involving ether/ethanol treatment, chloroform/methanol extraction, and chloroform/methanol elution from a silicic acid column, and is reported to increase the uptake of liposome by cultured Type II epithelial cells [Claypool et al., J. Clin. Invest., 74, 677-684 (1984)].

Wang et al., Fed. Proc., 44, 1024 (Abstract) (1985), describes two distinct small molecular weight proteins in rat lung surfactant one of which is soluble in ethanol, the other of which is soluble in ether/ethanol. However, these proteins are not reported as purified or characterized, and surfactant-like activity is not identified. Wang et al. indicate that these small molecular weight proteins may be involved with surfactant recycling. The smaller molecular weight proteins, such as those discussed above, may arise as proteolytic fragments of the larger SAP-35 molecule. However, it is unclear whether SAP-35, one or more of the smaller proteins, or all proteins together are active components imparting biophysical activity to natural mammalian pulmonary surfactant.

Tanaka et al., Chem. Pharm. Bull., 31, 4100-4109 (1983) describes a 10,000 molecular weight protein isolated by chloroform extraction of a fraction of minced bovine lung.

Fujiwara et al., Biochem., Biophys. Res. Comm., 135, 527-532 (1986), reports the isolation of a 5,000 dalton molecular weight proteolipid which, based on biophpysical testing, may have surface activity when mixed with phospholipids. However, this protein is not well-characterized in Fujiwara et al. The reported amino acid composition of a hydrophobic, small molecular weight protein of M_r=5,000 isolated from bovine surfactant extracts appears to be similar to, but is

distinguished by a paucity of valine residues in a reported amino acid composition from, a surfactant-associated protein according to the present invention, SAP(Val), the amino acid sequence of which is identifiable by a high number of valine residues. [Takahashi et al., Biochem. J., 236, 85-89 (1986)]. A small molecular weight protein with composition consistent with the protein previously termed "surfactant apolipoprotein B" [King et al., Am. J. Physiol., 224, 788-795 (1973)] is identifiable as a C-terminal domain of SAP-35 [Ross et al., J. Biol. Chem., 261, 14283-14291 (1986)]. Mixtures of phospholipids and a surfactant-associated protein of 35,000 daltons, SAP-35, or its fragments are reported to have relatively weak surface active properties compared to the surfactant proteolipids M_r=6,000-14,000 [Whitsett et al., Pediatr. Res., 20, 460-467 (1986); and Ross et al., J. Biol. Chem., 261, 14283-14291 (1986)].

In Schilling et al., PCT Application No. WO86/03408, a human 35,000 dalton protein and nonhuman 10,000 dalton proteins are described. Schilling et al. indicates that both classes of proteins may be needed to confer full biophysical activity upon surfactant phospholipids. Schilling et al. also discloses a complete DNA sequence encoding the 35,000 dalton protein, NH_2-terminal amino acid sequences for the 10,000 dalton nonhuman proteins and a preliminary (81 bp) partial sequence for a human cDNA clone for the 10,000 dalton protein. The 10,000 dalton canine and 81 bp human sequences have substantial regions indentical in sequence to the sequence of human SAP(Phe) according to the present invention.

In Taeusch, PCT Patent Publication No. WO 87/02037, two separate proteins are characterized by molecular weights of about 35 kd and two separate proteins are characterized by molecular weights of about

5.5-9 kd. The two approximately 6 kd proteins differ significantly from each other with respect to amino acid composition, as well as from the protein described in Tanaka, Chem. Pharm. Bull., 31l, 4100 (1983). Additionally, the N-terminal peptide sequence of the cold butanol-insoluble 6 kd protein is disclosed as well for a cDNA and deduced amino acid sequence for human SAP(Phe).

Monoclonal antibodies raised against alveolar surfactant protein are disclosed in Lewicki, U.S. Patent No. 4,562,003.

Hydrophobic small molecular weight proteins soluble in organic solvents are detectable in a variety of mammalian surfactants [Phizackerly et al., Biochem. J., 183, 731-736 (1979); Tanaka et al., Chem. Pharm. Bull., 31, 4100-4109 (1983); Suzuki, J. Lipid Res., 23, 62-69 (1982); Claypool et al., J. Clin. Invest., 74, 677-684 (1984); Yu et al., Biochem. J., 236, 85-89 (1986); Takahashi et al., Biochem. Biophys. Res. Commum., 135 527-532 (1986); Whitsett et al., Pediatr. Res., 20, 460-467 (1986); and Whitsett et al., Pediatr Res., 20, 744-749 (1986)]. SAPs, identifiable as proteins of M_r 6,000-14,000 are identified in the ether-ethanol extracts of surfactant preparations used clinically for treatment of hyaline membrane disease [Whitsett et al., Pediatr. Res., 20, 460-467 (1986); Whitsett et al., Pediatr Res., 20, 744-749 (1986); Fujiwara et al., Lancet, 1, 55-59 (1980); Enhorning et al., Pediatrics, 76, 145-153 (1985); and Kwong et al., Pediatrics, 76, 585-592 (1985)]. cDNAs encoding one of these proteins, human surfactant proteolipid with amino terminus of phenylalanine, designated herein as "SAP(Phe)," an M_r=7,500 peptide derived from an M_r=40,000 precursor, are disclosed in Glasser et al., Proc. Nat'l Acad. Sci. (USA), 84, 4007-4011 (1987) and Jacobs et al., J. Biol. Chem., 262, 9808-9811 (1987).

cDNA encoding a protein homologous to SAP(Phe), SP-18, is reported to be isolated from canine lung [Hawgood et al., Proc. Nat'l Acad. Sci. (USA), 84, 166-170 (1987)]. Reconstitution of small molecular weight weight surfactant proteins with synthetic phospholipids imparts virtually complete surfactant-like properties to the mixture, including rapid surface absorption and decreased surface tension during dynamic compression [Yu et al., Biochem. J., 236, 85-89 (1986); and Takahashi et al., Biochem. Biophys. Res. Commum., 135, 527-532 (1986)].

Summary of the Invention

SAP(Val) and SAP(Phe) according to the present invention are isolated, substantially pure, hydrophobic surfactant-associated proteins of 4,000-7,000 dalton simple molecular weight which, when isolated from animal tissue, comprise at least two hydrophobic proteins of molecular weights of 4,000-7,000 daltons each and may also comprise larger multimers thereof. It may be noted that SAP(Val) is also referred to in publications as "SAP-6(Val)," as SPL(pVAL)" and as "SP-C." Similarly, SAP(Phe) is referred to in publications as "SAP-6(Phe)," "SPL-(Phe)" and "SP-B."

Hereinafter, discussions related to SAP(Val) and SAP(Phe) are intended to apply to isolates; recombinant form; multimers; chemically or enzymatically synthesized forms; deletion, substitution or addition analogs; and analogs based on a hydropathy profile or on secondary and tertiary structure.

SAP(Val) and SAP(Phe), when combined with lipids, have significant pulmonary biophysical surfactant activity that may be utilized to effectively treat and prevent HMD and other syndromes associated with lack or insufficient amounts of natural pulmonary

surfactant material. Although it is presently believed that SAP(Val) and SAP(Phe) are lung-specific, their pulmonary biophysical surfactant activity is believed not to be species-specific. Therefore, SAP(Val) and SAP(Phe) may be purified from animal tissue, specifically pulmonary tissue or amniotic fluid, extracted from a variety of animals, such as dog, cow, human, pig, rabbit, rat and the like, or made by recombinant DNA methods or direct peptide synthesis. The concentration of SAP(Val) and SAP(Phe) in pulmonary tissue and lavage is probably greater than that found in aminotic fluid. With respect to other animal tissues or fluid, however, SAP(Val) and SAP(Phe) are believed to be present in substantially smaller or undetectable concentrations or completely absent.

It is believed that when SAP(Val) and SAP(Phe) are combined with lipids, they enhance the surfactant properties of the lipids imparting to the combination significant pulmonary biophysical surfactant activity. As a result of this remarkable property, such a combination is highly useful for replacing or supplementing natural pulmonary surfactant material and for reducing or maintaining normal surface tension in the lungs, especially in the lungs of patients suffering from HMD and other syndromes associated with the lack or insufficient amounts of natural pulmonary surfactant material. Because SAP(Val) and SAP(Phe) may be highly purified from animal tissue, or made by recombinant DNA techniques or by direct peptide synthesis, the immunologic risks currently associated with the less pure preparations available heretofore for treating or preventing HMD or related syndromes are substantially reduced.

It is to be understood that the terms "hydrophobic surfactant-associated protein" and "SAP(Val) or SAP(Phe)" are used interchangeably herein,

and that whenever referenced herein, they are meant to include any small hydrophobic surfactant-associated proteins having surfactant-like activity, having simple molecular weights of about 4,000-7,000 daltons determined in polyacrylamide gels containing sodium dodecyl sulfate and having substantial resistance to protease enzymes, endoglycosidase F and collagenase. These terms are also meant to include any such proteins or polypeptides having surfactant-like activity which are made by recombinant DNA methods or direct peptide synthesis comprising the amino acid sequences of such hydrophobic surfactant-associated proteins or translations of DNA sequences or portions thereof encoding such proteins, or deletion, substitution, or addition analogs of such proteins.

It is also to be understood that the term "hybridization" as used herein is meant to encompass conditions within a range of functional equivalents to and generally according to the conditions set forth in Examples 6, 7, 11, 12, 15 and 16.

The present invention further resides in a method of separating SAP(Val) from animal tissue which involves separating the animal tissue into a particulate fraction and a liquid fraction, and extracting SAP(Val) in a substantially pure state from the liquid fraction. The methods substantially reduces risks currently associated with the less pure preparations available heretofore for treating or preventing HMD or related syndromes.

The methods of this invention are further concerned with separating SAP(Val) from the larger, novel hydrophobic multimers thereof by, for instance, gel electrophoresis or other suitable techniques.

Also described are methods for isolating genes encoding SAP(Val) and SAP(Phe), the characterization of these genes, and methods for making SAP(Val) by

recombinant DNA methods and direct peptide synthesis.

In accordance with the present invention, SAP(Val) and SAP(Phe) may also be made by recombinant DNA methods. The following are examples of such methods. In summary, human lung poly(A)$^+$ RNA was used as a template to synthesize complementary DNA (cDNA) copies of which were subsequently cloned into a lambda vector in E.coli. cDNA copies of the genes encoding SAP(Val) and SAP(Phe) were identified, and then characterized by DNA sequence analysis. These DNA sequences allowed for further characterization of SAP(Val) and SAP(Phe) by comparison with the amino acid sequences for both SAP(Val) and SAP(Phe). In addition, the cDNA encoding SAP(Phe) was expressed as a fusion product with the E.coli ß-galactosidase (lacZ) gene, and the resulting expressed gene product has been shown to be antigenic by reacting with polyclonal antisera specific for SAP(Phe).

Polypeptides may be made by chemical or enzymatic synthesis based on the sequences given herein including the NH_2-terminal amino acid sequences given in Tables 2 and 3 and the translation of DNA sequences given in FIGS. 5 and 6. These chemically synthesized polypeptides include replicas of the amino acid sequences of SAP(Val) or SAP(Phe) or translations of DNA sequences encoding SAP(Val) or SAP(Phe) or portions of these sequences, as well as addition, deletion and substitution analogs of such replicas. The synthetic polypeptides may then be combined with lipids for surfactant preparations. Although these synthetic polypeptides may have a molecular weight less than SAP(Val) or SAP(Phe) isolated from animal tissue, it is to be understood that the terms "SAP(Val)" and "SAP(Phe)," as used herein, encompasses these synthetic peptides.

In particular fragments of synthetic peptides

having less than all, more particularly less than 75% and especially less than 50% of the coding region of SAP(Phe) or SAP(Val) are provided according according to the present inventor.

The present invention also includes novel medicaments, preparations, and methods employed to treat animals, including humans, suffering from HMD and other syndromes related to the lack or insufficient amounts of natural pulmonary surfactant material. Antibodies and antisera according to the present invention may be made which are directed against SAP(Val) or SAP(Phe).

Brief Description Of The Figures

FIG. 1 is an illustration of an SDS-PAGE preparation of SAP(Val) isolated from bovine lung;

FIG. 2 is an illustration of an SDS-PAGE preparation of SAP-6 from human, canine and bovine lung.

FIG. 3 is a nucleotide sequence and deduced amino acid translation of a partial cDNA clone encoding SAP(Phe);

FIG. 4 is a schematic depiction of the structure of SAP(Val) cDNA clones according to the present invention;

FIG. 5 is a nucleotide sequence and deduced amino acid translation of complete SAP(Val) cDNA;

FIG. 6 is a nucleotide sequence and deduced amino acid translation of complete SAP(Phe) cDNA;

FIG. 7 is a flow chart of the construction of a lacZ/SAP-6-Phe fusion product;

FIG. 8A is an illustration of the organization of the SAP(Phe) gene and FIG. 8B is a nucleotide sequence of a genomic clone encoding of SAP(Phe);

FIG. 9 depicts restriction maps and illustrates the organization of two SAP(Val) genes;

at Mr=65,000-70,000. Standard molecular weight markers are seen on the right. There is the possibility that SAP(Phe) is migrating between the 6,000 and 14,000 molecular weight regions, which may arise as a result of proteolysis of a precursor protein. Thus, there may be a slight heterogeneity of the forms between 6,000 and 14,000 which may reflect variable proteolytic processing of both SAP(Phe) and SAP(Val) precursors.

Therefore, at least two distinct 4,000-7,000 dalton SAP monomers exist that are believed to co-elute together, to co-purify together via gel electrophoresis migration, to have similar molecular weights of about 4,000-7,000 daltons determined in a polyacrylamide gel containing sodium dodecyl sulfate, to have similar biophysical surfactant-like activity and to have similar enzyme resistance. Further, it is believed that the larger multimers, i.e., M_r=18,000 and 26,000, resulting from one or more SAP(Val) and/or SAP(Phe) monomers are possibly bonded together via sulfhydryl bonds in view of their migration patterns in the absence and presence of ß-mercapoethanol, as illustrated in FIGS. 1 and 2. Therefore, it should be understood that any 4,000-7,000 dalton hydrophobic surfactant-associated proteins, SAP(Val) and SAP(Phe), are well within the contemplation of this invention.

EXAMPLE 4

Extraction of mRNA

RNA was extracted from lung tissue of an adult male immediately after death. Tissue was provided by the National Diabetes Tissue Interchange, Washington, D.C. The RNA was extracted by the method of Chirgwin et al., Biochem., 18, 5294-5499 (1979). Poly(A)$^+$ RNA was isolated by purification through oligo(dT) column

chromatography essentially as described in Maniatis et al., Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982) (hereinafter referred to as Maniatis et al.). A cDNA library was constructed in λ gtll as described by Young et al., Proc. Nat'l Acad. Sci. (USA), 80, 1194-1198 (1983).

EXAMPLE 5

Immunological Screening of cDNA Library

Polyclonal rabbit antisera were raised against bovine surfactant proteolipid, prepared from chloroform/methanol extraction of bovine lung surfactant [see Notter et al., Chem. Phys. Lipids, 33, 67-80 (1980), and were preabsorbed to minimize nonspecific background to E. coli proteins in a screening procedure. The preabsorption was done by the following procedure. An E. coli strain Y1090 lysate was disrupted by treatment with EDTA (pH 8.0) followed by sonication on ice with six bursts from a Branson sonifier at 50 watts for 10 seconds each. The sonicate was centrifuged at low speed to clear the supernatant. This supernatant was incubated with the above antisera for 48 hours at 4°C, then centrifuged to remove antibody/antigen complexes.

The library was plated on E. coli strain Y1090 at 20,000 pfu per 150 mm dish, grown for 5 hours at 42°C. and then blotted to nitrocellulose filters soaked in 10 mM isopropylthiogalactoside (IPTG). Filters were incubated overnight at 37°C. and then blocked for 1 hour at 4°C. in 50 mM Tris HCl, pH 7.4, 150 mM NaCl (TBS), and 50 gm/L powdered milk. Primary antibody reactions were conducted at a dilution of 1:1000 by incubation with the filters at 4°C. overnight. The filters were

then incubated with horseradish peroxidase conjugated goat anti-rabbit IgG (GAR-HRP) at a dilution of 1:3000 at 4°C. for 16 hours. Color was developed with 4-chloro-1-napthol for 3-5 minutes and reactions were then terminated by serial washings in distilled H_2O. Second and third screens were performed at 10-fold and 100-fold less phage per plate to identify isolated plaques.

EXAMPLE 6

Synthesis Of Oligonucleotide Probes

An oligonucleotide of mixed sequence was made using the phosphoramidite method of Matteucci and Caruthers, J. Am. Chem. Soc., 103, 3185-3191 (1981) on an Applied Biosystems DNA synthesizer Model No. 380A. The sequence for the probes was $(GTN)_6G$ wherein N is either deoxycytidine or deoxyinosine [Wood et al., Proc. Nat'l Acad. Sci. (USA), 52, 1585-1588 (1985)]. This sequence was based on the stretch of valine residues seen in human, canine and bovine SAP(Val) NH_2-terminal amino acid sequences shown in Table 2. The uniqueness of the valine stretch in SAP(Val) allowed for remarkable selectivity in the screening of the cDNA library. Due to the codon redundancy in this region, it would not have been feasible to utilize this region as a template for a probe without the use of deoxyinosine and the selection of deoxycytidine as a preferred base in the third position.

A second oligonucleotide probe was synthesized corresponding to the reverse translation of the 9 amino acids of the NH_2-terminal sequence of human SAP(Phe) seen in Table 2. The sequence of this probe was 5'-CCAICAITAIGGIATIGGIATIGGIAA-3', where I stands for deoxyinosine.

EXAMPLE 7

Screening With Oligonucleotide Probes

The positive clones selected with bovine surfactant polyclonal antisera were plated out by spotting 1 ul of a phage supernatant on a lawn of E. coli strain Y1090 (Δ lac U169 pro A^+ lon ara D139 strA supF {trpC 22:Tn10} pMC9) (Clontech Laboratories, Palo Alto, California). The plates were incubated at 42°C. for 5-6 hours and then removed and overlaid with nitrocellulose filters. The filters were removed and denatured in 1.5 M NaCl, 0.5 M NaOH for 1 minute, neutralized in 0.5 M Tris, pH 8.0, 1.5 M NaCl for 5 minutes, rinsed in 2 X SSPE (20 X SSPE = 3.6 M NaCl, 200 mM NaH_2PO_4, 20 mM EDTA, pH 7.4), and air dried. The filters were then baked for 1 hour at 80°C. in a vacuum oven. Filters were prehybridized for 6 hours at 45°C. in prehybridization buffer (5 X SSPE, 5 X Denhardt's, 50 mM sodium phosphate pH 7.0, 1 mM sodium pyrophosphate, 100 uM ATP, 50 ug/ml boiled salmon sperm DNA). While the filters were prehybridizing, the SAP(Val) oligonucleotide probe described in Example 6 was end-labeled with T_4 polynucleotide kinase and γ-^{32}P-ATP essentially as described by Maniatis et al., "Molecular Cloning: A Manual," Cold Spring Harbor, New York (1982). The SAP(Val) probe was added to the prehybridization buffer at a concentration of approximately 12 ng/ml, the filters were added, and incubated at 30°C. overnight. The filters were then washed in 0.2 X SSPE, 0.1% sodium dodecyl sulfate (SDS) at room temperature for 30 minutes, then at 32°C. for 45 minutes in fresh wash solution. They were then air-dried and subjected to autoradiography. This procedure

was repeated with a second set of filters using the SAP(Phe) probe described in Example 6.

When the above procedures were completed for both the SAP(Val) and SAP(Phe) probes, it was found that only the SAP(Phe) probe hybridized to any of the clones. The reason for this is not clear, but it is theorized that the antisera used for screening the cDNA library was only sensitive enough to detect SAP(Phe). This may have been because the SAP(Val) was not present in large enough quantities in the bovine lung surfactant preparation used for immunization to elicit an immunogenic response or because the SAP(Val) was less immunogenic than the SAP(Phe). As will be readily appreciated by those skilled in the art, this could be overcome by use of purification and screening of polyclonal antisera prior to use or by use of specific monoclonal antibodies.

Another approach which was used was to simply screen the cDNA library directly for clones encoding SAP(Val) using the SAP(Val) oligonucleotide of Example 6, end-labeled as described above. The cDNA library was plated out at approximately 30,000 pfu per 150 mm dish. The plates were incubated at 37°C. overnight then removed and overlaid with nitrocellulose filters. After the first set of filters was removed, a duplicate lift was made from each plate. Both sets of filters were treated as described above, with the following changes. Prehybridization was done in 6 X SSPE, 90 mM sodium citrate pH 7.6, 2 X Denhardt's, and 500 ug/ml boiled salmon sperm DNA at 37°C. for 5 hours. Hybridization was done in 6 X SSPE, 1 X Denhardt's, 50 ug/ml boiled salmon sperm DNA with a probe concentration of 1.5 ng/ml. The filters were hybridized at 55°C. for 1 hour then overnight at 37°C. They were washed in 6 X SSPE 2 times at room temperature and then 2 times at 37°C. Clones found to hybridize to the probe

on both sets of filters were isolated and purified by replating and screening at lower densities.

EXAMPLE 8

Characterization Of SAP(Val) and SAP(Phe) cDNA Clones

Several clones found to hybridize with either the SAP(Val) or SAP(Phe) probes were subcloned into the EcoRI site of E. coli plasmid puC19 (described in Yanisch-Perron et al., Gene, 33, 108-119 (1985)) for further characterization. The clones selected using the SAP(Phe) probe were mapped by restriction analysis, and then a clone was selected for further characterization by sequence analysis. This clone was subcloned into an M13 sequencing vector (described by Messing et al., Methods in Enzymology, 101, 70-78 (1983) and sequenced using M13 oligonucleotide primers according to standard methodologies as described by Sanger et al., Proc. Nat'l Acad. Sci. (USA), 74, 5463-5467 (1977). E. coli JM103 of JM109 (Pharmacia, Inc., Piscatawy, NJ) were used for growth of pUC plasmid and M13 phage subclones. The sequence of this SAP(Phe) clone is shown in FIG. 3. Underlined in this figure is the region which corresponds to the NH_2-terminal amino acid sequence for human SAP(Phe) shown in Table 3.

Nucleotide sequence analysis of one SAP(Val) clone, designated 334.2, of 0.3 kilobases comprised an open reading frame predicting close identity to the amino acid sequence determined directly from the human protein and was used to isolate other clones from the same cDNA library, as illustrated in FIG. 4. Sequence analysis of nine unique clones resulted in a consensus sequence predicting a larger polypeptide precursor.

In FIG. 4, clone 334.2 is the initial SAP(Val)

isolate and was used as a probe for re-screening of the cDNA library. Clones 311.3 and 13-1 have an 18 base pair deletion not seen in clones TP9-1 and TP11-2. In FIG. 4: a notched box indicates the valine rich hydrophobic domain of SAP(Val) clones; "A" denotes ApaL1, a restriction endonuclease that cleaves phage λ DNA infrequently and cuts at the start of the valine rich domain of SAP(Val); P=PstI; S=SmaI; a "*" indicates a sequence obtained from human lung mRNA directed dideoxy sequencing utilizing 5' SAP(Val) oligo primers.

In FIG. 5, the nucleotide sequence was determined using overlapping cDNA clones 311.3, 13-1, TP11-2, TP9-1 and RJ2-1. The broken under line indicates sequence from mRNA directed dideoxy sequencing using RJ2-1 as a primer that is present from sequence of the first exon of the SAP(Val) genomic clone VG519. Solid underlined amino acid sequence obtained directly on human SAP(Val) protein. The predicted sequence and obtained sequence match at 16 or 17 amino acids, the difference being His_{32} instead of Asn. Overlined DNA sequence is the 18 bp sequence that is absent in cDNA clones 311.3 and 13-1.

The Ile-Pro-Cys-Cys peptide was found within the reading frame of a larger polypeptide suggesting that the hydrophobic peptide of M_r=4,000-7,000 arises from proteolytic processing of a precursor protein at both the amino- and carboxy-terminus.

Full length cDNAs were not detected within this human lung library. RNA sequencing and analysis of genomic DNA were therefore utilized to predict the complete SAP(Val) mRNA.

A direct nucleotide sequence of SAP(Val) RNA was derived from human lung RNA. Dideoxynucleotide RNA sequencing was done by a modification of one procedure described by Geliebter et al., Proc. Nat'l Acad. Sci. (USA), 83, 3371-3375 (1986). An oligonucleotide primer specific for the 5' terminus of SAP(Val) cDNA was synthesized and end-labelled. Poly $(A)^+$ mRNA (6 µg) and [^{32}P]labelled primer (5 ng) were heated at 80°C for 3 minutes in 10 µl of annealing buffer (0.25 M KCl, 10 mM Tris, pH 8.3) and then allowed to anneal for 45 minutes at 50°C.

RNA template:primer solution (2 µl) was added to 3.3 µl of transcription buffer (24 mM Tris pH 8.3, 16 mM $MgCl_2$, 8 mM dithiothreitol, 0.4 mM dATP, 0.4 mM dCTP, 0.4 mM dTTP, 0.8 mM dGTP, 100 µg/ml actinomycin D) containing 5 units of AMV reverse transcriptase (Amersham) and 1 µl of one dideoxynucleotide triphosphate (0.5 mM ddGTP, 0.285 mM ddATP, 1.0 mM ddTTP, or 0.15 mM ddCTP). The reactions were incubated at 50°C for 45 minutes, heated at 80°C for 3 minutes in loading buffer (10 mM EDTA, 0.2% bromphenol blue, 0.2% xylene cyanol in 100% formamide), then loaded onto a sequencing gel.

Analysis after autoradiography revealed that the RNA sequence overlapped with the cDNA sequence and ended at a clear stop.

The SAP(Phe) cDNA clones isolated by antibody screening and oligonucleotide hybridization were incomplete on the 5' and 3' ends. Several of these cDNA clones were used as hybridization probes to isolate additional cDNA clones from the library. Sequence analysis of one of these clones showed it to be complete on both 5' and 3' ends. This sequence is shown in FIG. 6. The SAP(Phe) transcript encodes a precursor protein of approximately 42 kilodaltons.

In order to determine the exact 5' end of the

transcript, S1 nuclease mapping was performed using with a fragment from the 5' end of the SAP(Phe) genomic clone described in Example 11. Probes were prepared and S1 nuclease protection was done by the method of Kay et al., Mol. Cell. Biol. 6, 3134-3143 (1986). In addition, adult human lung poly(A)$^+$ RNA was sequenced directly as described above. Both the S1 mapping and the direct RNA sequencing identified the 5' end as shown in FIG. 6.

The hydrophobic regions of SAP(Phe) and SAP(Val) as shown in FIGS. 3 and 5 in parentheses are somewhat homologous. Although these two proteins are encoded by distinct genes, it is believed that they are structurally related. Therefore, these proteins may be members of a family of related proteins which bind phospholipids and are useful in surfactant replacement therapy and diagnosis.

EXAMPLE 9

Expression of LacZ/SAP(Phe) Fusion Protein in E.coli

The SAP(Phe) cDNA clone shown in FIG. 3 was inserted into the EcoRI site of plasmid pUC9 in the same orientation as the lacZ gene. The reading frame was then altered by cutting the plasmid DNA with the restriction enzyme SalI, then filling in the ends with T_4 polymerase and deoxynucleotides. This resulted in the insertion of 5 nucleotides within the lacZ gene upstream from the site of the fusion with the SAP(Phe) cDNA. This then led to the production of a lacZ/SAP(Phe) fusion product, which contains approximately 2400 daltons of lacZ at the NH_2-terminal end of the SAP(Phe) gene product. FIG. 7 shows a schematic diagram of this construction.

EXAMPLE 10

Testing of Fusion Protein
With SAP(Phe) Polyclonal Antisera

E.coli strain JM109 containing the plasmid described in Example 9 was grown up at 37°C. until the optical density at 600 nm reached 0.5, then IPTG was added to a concentration of 1 mM. The cells were grown for an additional 3-4 hours at 37°C. then pelleted and resuspended in 1/15th volume lysis buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 5% ß-mercaptoethanol, 0.1 mg/ml bromphenol blue). The samples were boiled for 5 minutes and loaded on a 12.5% Laemmli electrophoresis gel (Laemmli, Nature, 227, 680-685 (1970). After the gel was run, the proteins were transferred to nitrocellulose essentially by the method of Towbin et al., Proc. Nat'l Acad. Sci. (USA), 76, 4350-4354 (1979).

The nitrocellulose filter was preblocked in TBS containing 50 gm/l powdered milk at room temperature for 1 hour, then incubated with the preabsorbed antisera described in Example 5 at a dilution of 1:1000 at room temperature overnight. After this, the filter was washed 2 times in TBS, then incubated with GAR-HRP at a dilution of 1:2000 for 1 hour at room temperature.

A color reaction was developed as described in Example 5. FIG. 7 shows results of this test. Lane B contains the lacZ/SAP(Phe) fusion protein, while lane A contains protein from cells containing the plasmid which had not undergone the fill-in as described in Example 9. The SAP(Phe) antisera of Example 5 recognized proteins of 32,000-34,000 daltons in molecular weight which is in agreement with the predicted size of the translation product from the open reading frame of the SAP(Phe) clone plus the 2400 dalton portion of lacZ.

Southern blot analysis of genomic DNA after digestion with various restriction endonucleases. Southern blot analysis was performed using random primer labelled probes labelled with the random primer labelling technique (Pharmacia, Inc., Milwaukee, Wisconsin) hybridized with the DNA in 5 X SSC, 5 X Denhardt's solution, 0.1% SDS at 65°C. The nitrocellulose filters were washed twice (5 minutes each) at room temperature in 2 X SSC, 0.1% SDS, then twice in 2 X SSC, 0.1% SDS at 65°C. and four times in 0.2 X SSC, 0.1% SDS at 65°C. (20-30 minutes per wash). DNA fragments were subcloned into M13 vectors for dideoxy sequencing.

An oligonucleotide based on the overlapping sequence was synthesized and utilized to locate this 5' exon from genomic DNA encoding SAP(Val): 5'A-G-C-A-A-G-A-T-G-G-A-T-G-T-G-G-G-C-A-G-3'. Sequence from the 5' coding region of genomic clone λVG519 overlapped exactly with the direct RNA sequence and the 5' cDNA sequences. This genomic sequence is in the first exon of the SAP(Val) gene located 30 base pairs downstream from a consensus TATAA sequence further identifying the 5' untranslated region of the SAP(Val) RNA.

The 5' untranslated portion of the mRNA contains a potential initiation site which fits the criteria for a mammalian ribosomal binding site. There are two potential ATG start sites (bases 26 and 53) at the 5' end of the mRNA, the more 3' one most closely meeting selection criteria. The 3' end of several cDNAs demonstrates a polyadenylation addition sequence predicting the end of SAP(Val) RNA. Two distinct classes of cDNA were isolated which encode the SAP(Val) active region, the predicted mRNA differing in the coding region 3' to the active M_r=4,000-7,000 peptide, wherein a deletion of 18 base pairs may result in two distinct polypeptide precursors differing by six amino acids. However, this deletion does not arise from

nucleotide differences in the 2 types of genomic clones isolated for SAP(Val). Both clones contain the 18 base pair sequence deleted in one class of cDNA. This deletion may arise by alternative splicing, as there are 2 sets of sequences which conform to intron-exon splice sites just before and after the 18 base pairs in the genomic clones.

The deleted sequence is located at the start of exon 5 and is preceeded by six nucleotides (TTCCAG) which are also found at the end of exon four. Sequences at the 5' proximal end of exon five show two sets of sequence that conform to an intron-exon splice site consisting of a 10-15 base pair polypyrimidine tract followed by the dinucleotide AG, signaling the end of intronic sequence. The base pairs (CTCACTTCCTACATTCC) comprise a 17 base pair tract preceeding the AG of the major cDNA species. A second sequence (TGCTCTCTGC) preceeds the AG at the end of the deleted 18 base pair sequence and may represent an alternate splice site to account for the two observed SAP(Val) cDNA clones. If splicing occurs by a scanning mechanism, then this downstream alternate site may be less favored and result in the minor species lacking the 18 bp of cDNA. Only two of the nine SAP(Val) cDNAs detected during cDNA cloning contained this 18 base pair deletion. In summary, it appears that the 18 bp cDNA deletion arises from alternative splicing. It remains possible that the 18 base pair deletion resides in an allele of the SAP(Val) genes not detected in the present study.

Restriction endonuclease mapping of twelve clones identified by hybridization with SAP(Val) cDNA clone 334.2 demonstrated two distinct patterns of DNA fragments. Seven clones were represented by clone λVG519 and five clones were represented by clone λVG524. Restriction endonuclease fragments containing SAP(Val) coding regions were identified by their

hybridization with cDNA clone 334.2. A distinct 1.8 kb HindIII/EcoRI hybridizing fragment was identified in clone λVG519, while, a 4 kb HindIII hybridizing fragment was identified in clone λVG524. Both bands were reduced by 250 bp after digestion with ApaLl which cuts the SAP(Val) cDNAs in the region encoding the active hydrophobic peptide. Thus, these preliminary analyses delineated the restriction endonuclease fragments encoding SAP(Val) and were consistent with the restriction analysis of the cDNA clones encoding SAP(Val).

The restriction map and organization of the two SAP(Val) clones are represented in FIG. 9. In FIG. 9, The first two lines are restriction endonuclease maps of λVG519 and λVG524 representing two classes of restriction enconuclease patterns identified from the genomic clones. The third line is expanded from the second line and represents sequences in and near the gene for λVG524. Overbrackets identify sequences hybridizing to the SAP(Val) cDNA probe (exons 2-5). An ApaLl restriction site identifies the polyvaline domain. Restriction enconuclease sites are represented by the following letters: A = ApaLl; H = HindIII; B = BamHI; E = EcoRI; K = KpnI; and S = SmaI. Line C indicates the relative position of exons of SPL(Val). Open blocks indicate untranslated exons; dark blocks indicate translated exons.

The flanking regions of the genomic clones contained restriction site differences identified with SmaI, HindIII, and BamHI restriction enzymes. Restriction maps of the two classes of SAP(Val) genes were readily distinguishable by this analysis. Both SAP(Val) genes were composed of 6 exons and 5 introns from TATAA to the end of the 6th exon. The two SAP(Val) genes demonstrated few but clear differences in nucleotide sequence, as illustrated in FIG. 10.

In preparing FIG. 10, nucleotide sequence analysis was performed as described by Brunner et al., Biochemistry, 25, 5028-5035 (1986). Base pairs are numbered with +1 indicating the transcription initiation site determined as described above. Nucleotides 3' to this site are labelled as (+) and 5' nucleotides are labelled as (-). The overlined sequence TGACGTCA represents a potential cAMP recognition sequence; the sequences TCACCTCT and TATAA representing consensus promoter and sequences are overlined. Alternative donor/acceptor splice sequences are overlined at the 5' end of exon 5. The differences in sequence between λVG519 and λVG524 are shown by asterisks, dashes, and letters above the λVG519 sequence representing nucleotide insertions, deletions or substitutions, respectively.

Part of the first, fifth and the entire sixth exons of SAP(Val) are untranslated. The M_r=22,000 polypeptide precursor is encoded by exon 2, 3, 4, and 5. The most hydrophobic region of the peptide (beginning NH_2-Ile-Pro-Cys-Cys-Pro-Val...) is located within exon two which encodes a peptide of 44 amino acids.

Because complete cDNAs encoding SAP(Val) were not identified, RNA directed sequencing was performed to identify the nucleotide sequence from the available cDNA sequence to the transcription initiation site. A strong reverse transcriptase stop was detected in the RNA-directed sequence analysis. It is inferred that this demonstrates the site of transcription initiation.

To identify the 5' untranslated exon and upstream flanking sequences of the SAP(Val) genes, an oligonucleotide (3'-CAGCCAGATGGATGTGGGCAG-5') spanning the 5'-most cDNA and eight base pairs of extended RNA directed sequence was synthesized and used to analyze Southern blots of λVG519 and λVG524. Identical

restriction fragment patterns were detected in both classes of genomic clones with this oligonucleotide after digestion with KpnI and KpnI/HindIII. The 1.8 kb KpnI and 1.1 kb KpnI/HindIII fragments were sequenced and found to include nucleotide sequences from the 5'-most cDNA clone (clone RJ2-1) and the 5' nucleotide sequence derived from mRNA-directed sequence analysis.

A consensus promoter sequence TATAA was located 30 base pairs 5' to the predicted transcription initiation site in both clones. As used throughout the present application, distances are given with respect to the location of the 3' end of the sequence being discussed. The sequence TCACCTCT nearly matches a consensus eucaryotic promoter sequence TCAATCT in 6 of 7 nucleotides Breatnach et al., Ann. Rev. Biochem., 50, 349 (1981). It was located 55 nucleotides upstream of the transcription initiation site. A sequence, TGATGTCA, was located 504 base pairs upstream from the transcription initiation site and matches the sequence TGACGTCA in 7 of 8 base pairs. This latter element comprises a sequence previously associated with cAMP responsivity [Montminy et al., Proc. Nat'l Acad. Sci. (USA), 83, 6682-6686 (1986)]. Consensus sequences previously recognized as corticosteroid-responsive elements were not detected in these clones, although glucocorticoid enhanced SAP(Val) expression in organ culture of fetal lung.

The predicted protein sequence of the exons encoded by the λVG519 and λVG524 were identical. No differences were observed in the first five exons of the SAP(Val) gene and three nucleotide differences were detected in the sixth exon, which is untranslated. A high degree of homology was observed even in the introns of the SAP(Val) genes which varied by only 1%.

Hydropathy analysis of the predicted SAP(Val) precursor peptide demonstrates that the hydrophobic,

potentially membrane-associated domain of the M_r=22,000 precursor protein is contained within the second exon of both SAP(Val) genes. The predicted peptide domain derived from exons three and four are rich in charged amino acids which are not compatible with the amino acid composition of the SAP(Val) preparations. The location of the C-terminus of SAP(Val) peptide is suggested by its migration with markers of M_r=4,000-7,000 and by its hydrophobic properties, including its association with lipids and its solubility in organic solvents, all of which are consistent with its derivation primarily from the peptide encoded by the second exon. Proteolytic processing in both amino and carboxy termini may account for the generation of the smaller peptide detected in pulmonary surfactant.

No homology was noted between the 5' region of SAP(Val) and a published SAP-35 genomic clone.

The nucleotide sequence of λVG519 and λVG524 were entirely conserved in the amino acid coding region. The genomic sequences were identical to the SAP(Val) cDNA except for a single nucleotide difference in exon 5 in which leucine is encoded by CTG rather than the TTG observed in the cDNAs. Nucleotide differences were noted in only those exons encoding the 3' untranslated regions. Nucleotide sequence difference frequencies (1-2%) were similar in both introns and the 5' and 3' flanking sequences available for analysis (approximately 500 base pairs from the TATAA). The 5'-most fragment of λVG519 (600 bp HindIII fragments) was not present in λVG524 by Southern blot hybridization, demonstrating a difference in flanking sequence in that region.

The nearly complete conservation of the nucleotide sequence in the exons, the small divergence in the introns, and the differences in restriction mapping of the 3' and 5' regions are most consistent

with the interpretation that the SAP(Val) genomic clones represent two distinct gene loci encoding SAP(Val). However, these differences may be due to allelic variation.

The predicted amino acid sequence of the entire SAP(Val) precursor was deduced from the cDNA clones, RNA sequencing and the genomic DNA. The precursor comprises 188 or 197 amino acids depending on assignment of the N-terminal methionine (or 182 or 191 with the deletion) representing a 21,000 Dalton polypeptide. The size of the predicted polypeptide is consistent in size with the hybrid selected translation product of M_r=22,000. There was no discernable signal peptide at the amino terminus and the precursor polypeptide contain no asparagine-linked glycosylation sites, contrasting with the SAP(Phe) precursors which contain one or two potential asparagine-linked glycosylation sites. The SAP(Val) peptide begins at Gly_{25} or Ile_{26} and the domain including amino acids Leu_{37} to Ser_{61} is compatible with a membrane-associated or spanning domain of 25 amino acids. This region contains the repeated valine residues. The precise C-terminus of SAP(Val) has not been identified directly and numerous attempts to isolate proteolytic or CNBr fragments of the canine or bovine proteolipid have been unsuccessful.

However, NMR studies of bovine SAP(Val) support a tentative conclusion that the C-terminus is His-Thr, i.e. that SAP(Val) may comprise Gly or Ile to His(65) for a total of 40 or 41 amino acids.

The N-terminal amino acid sequences of the bovine and canine proteolipid preparations was greater than 90% SAP(Val) in multiple determinations. The predicted amino acid sequence of an M_r=4,000-7,000 peptides from the human cDNA predicts a hydrophobic peptide lacking in phenylalanine and tyrosine. In

contrast, tyrosine and phenylalanine are present in the amino acid sequence of the small molecular weight hydrophobic surfactant protein, human SAP(Phe). Lack of phenylalanine and tyrosine also distinguishes SAP(Val) from SAP(Phe) and from small molecular weight surfactant proteins previously reported.

It is believed that genomic sequences further the ability to clone and express SAP(Val) genes, e.g. by providing regulatory sequences which may be particularly useful for regulating expression.

EXAMPLE 13

SAP(Val) Poly(A^+) RNA Sequencing

SAP(Val) cDNA clones isolated by oligonucleotide hybridization were incomplete on the 5' and 3' ends. Additional clones were isolated using SAP(Val) cDNA for the hybridization probe. Several were found to be complete on the 3' end, but none on the 5' end. Two distinct classes of SAP(Val) cDNA were detected by sequence analysis, differing by the absence of 18 nucleotides in the 3' coding region of some cDNAs. The complete 5' sequence was determined by direct sequencing of adult human lung poly$(A)^+$ RNA and by S1 nuclease mapping of a 5' fragment from a SAP(Val) genomic clone as described for SAP(Phe). The complete sequence including the 5' end identified by these two methods is shown in FIG. 5. The SAP(Val) transcript encodes a precursor protein of approximately 21 kilodatons.

EXAMPLE 14

Chromosomal Location of SAP(Val) Gene

A [^{32}P]-labeled SAP(Val) cDNA clone was hybridized to DNA obtained from the mouse-human chromosomal panels. The [^{32}P]-labelled SAP(Val) clone was hybridized to mouse-human chromosomal hybrids containing all human chromosomes as previously characterized. Hybridization was only observed with hybrids containing chromosome 8.

EXAMPLE 15

SAP(Val) Northern Blot Analysis

Poly $(A)^+$ RNA was prepared and isolated by oligo (dT) cellulose chromatography from a fetal lung at 19 weeks gestation and human adult lung. Adult and fetal lung tissue was homogenized in buffer containing 4 M guanidine thiocyanate, 0.5% N-lauroyl sarcosine, 20 mM sodium citrate, 0.1 M s-mercaptoethanol and 0.1% antifoam A. RNA was extracted by centrifugation through a cushion of 5.7 M cesium chloride [Hsu et al., J. Histochem. Cytochem., 29, 577-580 (1981)]. The RNA pellet was dissolved in water, extracted with phenol and chloroform, and precipitated with ethanol. The amount of RNA in an aqueous solution was determined by optical density at 260 nm.

RNA (5ug) was separated on 1.2% agarose, 7% formaldehyde gels, transferred to nitrocellulose and hybridized [Weaver et al., J. Appl. Physiol., 61, 694-700 (1986)] with [^{32}P]SAP(Val) DNA clone 334.2 (1.4×10^6 cpm/ml, approximate specific activity 4×10^8 cpm/ug), washed and exposed to Kodak XAR-film at -70°C overnight.

Northern blot analysis of human lung RNA using a SAP(Val) cDNA probe as shown in FIG. 11 detected an approximately 0.9 kilobase RNA, distinct from that of SAP(Phe) or SAP-35 [Glasser, Proc. Nat'l. Acad., Sci. (USA), 84, 4007-4011 (1987); and Whitsett et al., J. Biol. Chem., 262, 5256-5261 (1987)]. SAP(Val) RNA was less abundant in human fetal lung (approximately 19-20 weeks of gestation) than in adult lung. The finding that the RNA for SAP(Val) is developmentally regulated is consistent with the possible role of SAP(Val) in surfactant function required for perinatal adaptation to air breathing at birth.

EXAMPLE 16

Hybrid Arrest Translation

Approximately 5 µg of EcoR1 restricted SAP(Val) cDNA was heat denatured at 100°C for 10 minutes and hybridized with 5 µg of human lung RNA for 2 hours at 50°C in 80% formamide, 10 mM Pipes, (pH 6.4), 0.25 mM EDTA and 0.4 M NaCl. Hybridization was terminated by the addition of 200 µl H_2O and 25 µg yeast tRNA. The solution was divided into two samples, one of which was melted at 100°C for 1 minute followed by rapid chilling, and the other which was preserved in hybrid form. Both samples were precipitated in ethanol and translated in a wheat germ transcription assay (Promega Biotec, Inc.) in the presence of 50 µCi [^{35}S]-methionine (New England Nuclear). The proteins were immunoprecipitated with anti-bovine surfactant proteolipid antiserum subjected to 11% SDS-PAGE, transferred to nitrocellulose and subjected to autoradiography.

Hybrid arrested translation and immunoprecipitation with antiserum generated against bovine proteolipid resulted in complete arrest of a

single M_r=22,000 polypeptide, as shown by the autoradiograph gels illustrated in FIG. 12. The M_r=22,000 peptide detected by hybrid arrested translation of human lung RNA was consistent with that predicted from the cDNA encoding SAP(Val) further distinguishing it from SPL(Phe) and SAP-35 polypeptide precursors of Mr=40,000 and M_r=26,000 respectively.

EXAMPLE 17

Expression of SAP(Val) in E. coli

A E. coli expression vector has been developed for expression of heterologous proteins as fusions with the E. coli protein CMP-KDO synthetase (CKS) [Goldman et al., J. Biol. Chem., 261, 15831-15835 (1986)]. This vector was deposited including a SAP(Val) insert as ATCC Deposit No. 67517, on September 29, 1987, with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852. The plasmid is a derivative of pWM111[Mandecki et al., Gene, 43, 131-138 (1986)] from which the EcoR1-HindIII fragment containing the promoter, operator, ribosome binding site, and C5A gene have been replaced with corresponding ones for CKS. The CKS gene is under the control of a wild type lac operator and a modified lac promoter, designated lacP-T9-D. The -9 position has been changed from G to T, and there is a 1 nucleotide deletion in the spacer region between the -35 and -10 regions. The plasmid also contains the trpA Rho-independent transcription terminator [Christie et al., Proc. Nat'l. Acad. Sci. (USA), 78, 4180-4184 (1981)] at the 3' end of the CKS gene. In addition, there is a linker region at the 3' end of the CKS gene which contains multiple restriction sites as well as an in-frame Asp-Pro. The peptide bond between Asp and Pro is acid-labile as described by

Landon, Meth. Enzymol., 47, 145-149 (1977). Under induced conditions (1 mM IPTG) when no insert is present, the CKS protein accummulates to levels >50% of the total cellular protein as shown in FIG. 13, lane 4.

In FIG. 13, a 10% SDS-PAGE stained with Coomassie brilliant blue is illustrated in which: lane 1 contained pre stained high molecular weight standards (BRL Life Technologies, Gaithersburg, Maryland); lane 2 contains E. coli total cell lysate (no plasmid); lane 3 contains E. coli total cell lysate with CKS/SAP(Val) expressed; and lane 4 contains E. coli total cell lysate with CKS alone expressed.

A DNA fragment containing the SAP(Val) cDNA was inserted into the multiple cloning site of this vector at the 3' end of the CKS gene. The two coding regions are in the same frame, so that expression results in a fusion protein containing the CKS protein and the entire SAP(Val) proprotein. The fusion protein is 48.7 kDal; 27.4 kDal from CKS and 21.3 kDal from SAP(Val). There is one Asp-Pro at the fusion junction between CKS and SAP(Val) and one located 20 amino acids in from the C-terminal end of SAP(Val). When a culture of cells containing this plasmid is grown under induced conditions, the CKS/SAP(Val) protein represents approximately 2-5% of the total protein as shown in FIG. 13, lane 3. The cells may be lysed by a variety of methods, one example being the use of lysozyme, sodium deoxycholate, and sonication as described in Marston et al., Bio/Technology, 2, 800-804 (1984). When lysed by this method, the CKS/SAP(Val) protein is in the insoluble pellet and may be purified away from the bulk of the E. coli proteins. The CKS/SAP(Val) protein represents >60% of the total insoluble protein as shown in FIG. 14, lanes 2 and 3.

FIG. 14 illustrates a 12.5% SDS-PAGE stained with Coomassie brilliant blue in which: lane 1 contains

pre stained high molecular weight standards (BRL Life Technologies, Gaithersburg, Maryland) lane 2 contains 1 µl of insoluble protein preparation; lane 3 contains 5 µl of insoluble protein preparation; and the arrow indicates CKS/SAP(Val) fusion protein.

Several conditions for acid cleavage of Asp-Pro bonds have been described by Szoka et al., DNA, 5, 11-20 (1986), and others. One example is the use of 70% formic acid for 24-48 hours at 37°C. When the isolated protein is treated in this way, the resultant nearly full-length SAP(Val) proprotein is insoluble and can be recovered by extraction with organic solvents.

Similar constructions can be made using the SAP(Val) or SAP(Phe) active regions alone. For example, the SAP(Val) active region, as encoded by nucleotides 100-222 of FIG. 5, may be assembled using synthetic oligonucleotides and inserted into the CKS expression vector. This construction can be designed with an Asp-Pro at the N-terminus of the active region. Acid cleavage at this bond would generate SAP(Val) containing an extra Pro at the N-terminus. As an alternative, assuming that the first 3 amino acids are Gly-Ile-Pro, one may replace the Gly-Ile with Asp such that acids cleavage would leave the SAP(Val) active region minus the first 2 amino acids. An alternative cleavage method using hydroxylamine might also be employed. This chemical cleaves at the peptide bond between Asn and Gly as discussed in Bornstein et al., Meth. Enzymol., 47, 132-145 (1977). Assuming that the SAP(Val) N-terminal amino acid is Gly, this cleavage method yields intact SAP(Val).

EXAMPLE 18

Expression of SAP(Val) and SAP(Phe) in Mammalian Cells

SAP(Val) or SAP(Phe) genomic or cDNA may be inserted into, for example, a mammalian expression plasmid adjacent to the herpes simplex type I (HSV) thymidine kinase (tk) promoter. This plasmid is then added to 1 ml HeBS (8 gm/l NaCl, 0.37 gm/l KCl, 0.25 gm/l Na_2HPO_4-12 H_2O, 1 gm/l dextrose, 5 gm/l Hepes buffer pH 7.1), and mixed well. 2.5M $CaCl_2$ is added to the mixture to a final concentration of 0.125 M while a gentle stream of air is bubbled through the mixture during the addition of the $CaCl_2$ and for an additional 30 seconds. The DNA is then allowed to precipitate for 30 minutes at room temperature and then 0.5 mls of the DNA suspension is added to 25 cm^2 dishes of baby hamster kidney cells, for example, or other mammalian cells of choice. Four hours after addition of the DNA, the culture medium is removed, the cells washed 1 time with Eagle's medium containing 5% fetal calf serum (EC-5), and 1 ml 25% dimethyl sulfoxide (DMSO) in HeBS is added to each dish for 4 minutes at room temperature. The 25% DMSO is then removed, the dish is washed 2 times with EC-5, and the cells are then incubated in EC-5. Twenty-four hours after addition of DNA, the cells are infected with HSV (10 pfu/cell) and the infection allowed to proceed for 48 hours. The expressed SAP(Val) or SAP(Phe) protein is then isolated from the culture fluids by, for example, immunoprecipitation and assayed by, for example, SDS-PAGE.

Genes encoding SAP(Phe) or SAP(Val) may also be expressed in any suitable expression system well-known to those skilled in the art. Examples of such expression systems include E. coli, Bacillus, yeast,

baculovirus or other mammalian cell expression systems.

The sequences shown in FIGS. 3, 5, 6, 8B and 10 indicate that the SAP(Phe) and SAP(Val) are derived from larger precursor proteins. It is believed, based upon a best current estimate of molecular weight of 7500 to 7800 daltons, that a 75-80 residue active portion of the larger precursor protein of SAP(Phe) is encoded by the nucleotide region shown in brackets in FIG. 6. Similarly, it is believed, based upon NMR (NOESY-COSY) analysis of bovine SAP(Val), that the active portion of the larger precursor protein of SAP(Val) is encoded by 120 or 123 nucleotides, depending upon assignment of N-terminus as Ile or Gly, respectively. This nucleotide region is shown in brackets in FIG. 5. Therefore, it should be apparent to those skilled in the art that expression of either SAP(Val) or SAP(Phe) may be accomplished through expression of the DNA encoding the larger precursor proteins followed by a processing step to further isolate the active portion of these proteins.

Alternatively, one skilled in the art recognizes that another approach for producing SAP(Val) or SAP(Phe) proteins is to express smaller regions of DNA encoding portions of the larger precursor proteins. For example, the region encompassing nucleotides 627-851 shown in brackets in FIG. 6 may be selected for expression of a 75 amino acid polypeptide which is homologous to SAP(Phe) at the NH_2-terminal end and has an approximate molecular weight of 7500 daltons.

It is also apparent to those skilled in the art that the genes encoding SAP(Phe) or SAP(Val) or portions of these genes can be made by chemical or enzymatic synthesis. Further, it should be apparent that deletion, substitution, or addition analogs of such

genes or portions of such genes may be made by techniques well known to those skilled in the art. Therefore, it should be understood that SAP(Val) or SAP(Phe) genes or portions thereof, whether isolated from genomic or cDNA libraries or made by chemical synthesis, and the proteins arising from expression of these genes, are well within the contemplation of this invention.

EXAMPLE 19

Synthesis Of A Polypeptide Based on Canine SAP(Val)

A polypeptide having the following sequence, NH_2-Tyr-Ile-Pro-Cys-Phe-Pro-Ser-Ser-Leu-Lys-Arg-Leu-Leu-Ile-COOH, was synthesized to provide a replica of the initial 13 NH_2-terminal amino acid residues of canine SAP(Val) and to include a terminal tyrosine residue allowing for potential labeling with ^{125}I. This polypeptide was assembled on a resin support by stepwise solid phase synthesis (starting with the carboxy terminal residue) according to the general procedure described in Barany et al., The Peptides, 2, Gross et al., eds., Academic Press, New York, 1284 (1980). A BOC-L-Ile-OCH_2-Pam resin was transferred to a reaction vessel on an Applied Biosystems Synthesizer, Model 430A.

Protected amino acids were coupled in a stepwise manner to the resin support by preformed symmetric anhydride chemistry, except in the case of arginine addition, wherein the DCC/HOBT protocol [Konig et al., Chem. Ber., 103, 788-798 (1970)] was employed. All NH_2-terminal residues were protected by t-butyloxy carbonyl (t-Boc) linkage, and side chains of various

WHAT IS CLAIMED IS:

1. A purified and isolated DNA sequence encoding SAP(Val).

2. A purified and isolated SAP(Val) nucleic acid described by a nucleotide sequence selected from the group consisting of:

the nucleotide sequence as illustrated in FIG. 5 or FIG. 10;

a nucleotide sequence comprising 20 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10;

a nucleotide sequence describing a nucleic acid which hybridizes with 20 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10;

a nucleotide sequence describing a nucleic acid which would hybridize with 20 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10 but for the redundancy of the genetic code; and

a nucleotide sequence encoding an epitope encoded by 18 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10.

3. A transformation vector comprising the nucleic acid of claim 2.

4. A cell transformed with the vector as recited in claim 3.

5. A method for obtaining purified and isolated SAP(Val) comprising the steps of:

culturing a cell as recited in claim 4 in a medium and under conditions favorable for expression of

SAP(Val); and

isolating SAP(Val) from the contents of the medium.

6. A purified and isolated SAP(Val) substantially free of other human proteins and encoded by a purified and isolated nucleic acid described by a nucleotide sequence selected from the group consisting of:

the nucleotide sequence as illustrated in FIG. 5 or FIG. 10;

a nucleotide sequence comprising 20 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10; and

a nucleotide sequence encoding an epitope encoded by 18 sequential nucleotides in the nucleotide sequence illustrated in FIG. 5 or FIG. 10.

7. A SAP(Val) synthetic polypeptide made by chemical or enzymatic peptide synthesis.

8. The synthetic peptide as recited in claim 7 having the following amino acid sequence:

Tyr-Ile-Pro-Cys-Phe-Pro-Ser-Ser-Leu-Lys-Arg-Leu-Leu-Ile.

9. The synthetic peptide as recited in claim 7 having the following amino acid sequence:

Leu-Ile-Pro-Cys-Cys-Pro-Val-Asn-Ile-Lys-Arg-Leu-Leu-Ile-Val-Val-Val-Val-Val-Val-Val-Val.

10. The synthetic peptide as recited in claim 7 having the following amino acid sequence:

Leu-Ile-Pro-Cys-Cys-Pro-Val-His-Leu-Lys-Arg-Leu-Leu-Ile-Val-Val-Val-Val-Val-Val-Leu-Ile-Val-Val-Val-Ile-Val-Gly-Ala-Leu-Leu.



FIG.1

FIG.2

```
GAA TTC CGG GAG TGC AAC GTC CTC CCC TTG AAG CTG CTC ATG CCC CAG TGC AAC CAA GTG   60
Glu Phe Arg Glu Cys Asn Val Leu Pro Leu Lys Leu Leu MET Pro Gln Cys Asn Gln Val

CTT GAC GAC TAC TTC CCC CTG GTC ATC GAC TAC TTC CAG AAC CAG ACT GAC TCA AAC GGC  120
Leu Asp Asp Tyr Phe Pro Leu Val Ile Asp Tyr Phe Gln Asn Gln Thr Asp Ser Asn Gly

ATC TGT ATG CAC CTG GGC CTG TGC AAA TCC CGG CAG CCA GAG CCA GAG CAG GAG CCA GGG  180
Ile Cys MET His Leu Gly Leu Cys Lys Ser Arg Gln Pro Glu Pro Glu Gln Glu Pro Gly

ATG TCA GAC CCC CTG CCC AAA CCT CTG CGG GAC CCT CTG CCA GAC CCT CTG CTG GAC AAG  240
MET Ser Asp Pro Leu Pro Lys Pro Leu Arg Asp Pro Leu Pro Asp Pro Leu Leu Asp Lys

CTC GTC CTC CCT GTG CTG CCC GGG GCC CTC CAG GCG AGG CCT GGG CCT CAC ACA CAG GAT  300
Leu Val Leu Pro Val Leu Pro Gly Ala Leu Gln Ala Arg Pro Gly Pro His Thr Gln Asp

CTC TCC GAG CAG CAA TTC CCC ATT CCT CTC CCC TAT TGC TGG CTC CTC TGC AGG GCT CTG ATC  360
Leu Ser Glu Gln Gln Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Cys Arg Ala Leu Ile

AAG CGG ATC CAA GCC ATG ATT CCC AAG GGT GCG CTA CGT GTG GCA GTG GCC CAG GTG TGC  420
Lys Arg Ile Gln Ala MET Ile Pro Lys Gly Ala Leu Arg Val Ala Val Ala Gln Val Cys

CGC GTG GTA CCT CTG GTG GCG GGC GGC ATC TGC CAG TGC CTG GCT GAG CGC TAC TCC GTC  480
Arg Val Val Pro Leu Val Ala Gly Gly Ile Cys Gln Cys Leu Ala Glu Arg Tyr Ser Val

ATC CTG CTC GAC ACG CTG CTG GGC CGC ATG CTG CCC CAG CTG GTC TGC CGC CTC GTC CTC  540
Ile Leu Leu Asp Thr Leu Leu Gly Arg MET Leu Pro Gln Leu Val Cys Arg Leu Val Leu

CGG TGC TCC ATG GAT GAC AGC GCT GGC CCA AGG TCG CCG ACA GGA GAA TGG CTG CCG CGA  600
Arg Cys Ser MET Asp Asp Ser Ala Gly Pro Arg Ser Pro Thr Gly Glu Trp Leu Pro Arg

GAC TCT GAG TGC CAC CTC TGC ATG TCC GTG ACC ACC CAG GCC GGG AAC AGC AGC GAG CAG  660
Asp Ser Glu Cys His Leu Cys MET Ser Val Thr Thr Gln Ala Gly Asn Ser Ser Glu Gln

GCC ATA CTA CAG GCA ATG CTC CAG GCC TGT GTT GGC TCC TGG CTG GAC AGG AAG AAG TGC  720
Ala Ile Leu Gln Ala MET Leu Gln Ala Cys Val Gly Ser Trp Leu Asp Arg Glu Lys Cys
```

FIG.3A

```
AAG CAA TTT GTG GAG CAG CAC ACG CCC CAG CTG CTG ACC CTG GTG CCC AGG GGC TGG GAT    780
Lys Gln Phe Val Glu Gln His Thr Pro Gln Leu Leu Thr Leu Val Pro Arg Gly Trp Asp

GCC CAC ACC ACC TGC CAG GCC CTC GGG GTG TGT GGG ACC ATG TCC AGC CCT CTC CAG TGT    840
Ala His Thr Thr Cys Gln Ala Leu Gly Val Cys Gly Thr MET Ser Ser Pro Leu Gln Cys

ATC CAC AGC CCC GAC CTT TGA TGA GAA CTC AGC TGT CCA GCT GCA AAG GAA AAG CCA AGT    900
Ile His Ser Pro Asp Leu End

GAG ACG GGC TCT GGG ACC ATG GTG ACC AGG CTC TTC CCC TGC TCC CTG GCC CTC GCC AGC    960

TGC CAG GCT GAA AAG AAG CCT CAG CTC CCA CAC CGC CCT CCT CAC CGC CCT TCC TCG GCA   1020

GTC ACT TCC ACT GGT GGA CCA CGG GCC CCC AGC CCT GTG TCG GCC TTG TCT GTC TCA GCT   1080

CAA CCA CAG TCT GAC ACC AGA GCC CAC TTC CAT CCT CTC TGG TGT GAG GCA CAG CGA GGG   1140

CAG CAT CTG GAG GAG CTC TGC AGC CTC CAC ACC TAC CAC GAC CTC CCA GGG CTG GGC TCA   1200

GGA AAA ACC AGC CAC TGC TTT ACA GGA CAG GGG GTT GAA GCT GAG CCC CGC CTC ACA CCC   1260

ACC CCC ATG CAC TCA AAG ATT GGA TTT TAC AGC TAC TTG CAA TTC AAA ATT CAG AAG AAT   1320

AAA AAA TGG GAA CAT ACA GAA CTC TAA AAG ATA GAC ATC AGA AAT TGT TAA GTT AAG CTT   1380

TTT CAA AAA ATC AGC AAT TCC GGA ATT C                                            1408
```

FIG.3B


SPL (pVal) cDNA
0
S
A
P
S
S
850
pVal
334.2
aataaa
pVal
311.1
pVal
TP11.2
aataaa
pVal
TP9.1A
pVal
RJ2-1
*

FIG.4

```
                                                30                                                  60
ACA GGA GAG CAT AGC ACC TGC AGC AAG ATG GAT GTG GGC AGC AAA GAG GTC CTG ATG GAG
                                    MET Asp Val Gly Ser Lys Glu Val Leu MET Glu
                                    1

                                                90                                                 120
AGC CCG CCG GAC TAC TCC GCA GCT CCC CGG GGC CGA TTT GGC ATT CCC TGC TGC CCA GTG
Ser Pro Pro Asp Tyr Ser Ala Ala Pro Arg Gly Arg Phe Gly Ile Pro Cys Cys Pro Val
                                                                  26

                                               150                                                 180
CAC CTG AAA CGC CTT CTT ATC GTG GTG GTG GTG GTG GTC CTC ATC GTC GTG GTG ATT GTG
His Leu Lys Arg Leu Leu Ile Val Val Val Val Val Val Leu Ile Val Val Val Ile Val

                                               210                                                 240
GGA GCC CTG CTC ATG GGT CTC CAC ATG AGC CAG AAA CAC ACG GAG ATG GTT CTG GAG ATG
Gly Ala Leu Leu MET Gly Leu His MET Ser Gln Lys His Thr Glu MET Val Leu Glu MET

                                               270                                                 300
AGC ATT GGG GCG CCG GAA GCC CAG CAA CGC CTG GCC CTG AGT GAG CAC CTG GTT ACC ACT
Ser Ile Gly Ala Pro Glu Ala Gln Gln Arg Leu Ala Leu Ser Glu His Leu Val Thr Thr

                                               330                                                 360
GCC ACC TTC TCC ATC GGC TCC ACT GGC CTC GTG GTG TAT GAC TAC CAG CAG CTG CTG ATC
Ala Thr Phe Ser Ile Gly Ser Thr Gly Leu Val Val Tyr Asp Tyr Gln Gln Leu Leu Ile

                                               390                                                 420
GCC TAC AAG CCA GCC CCT GGC ACC TGC TGC TAC ATC ATG AAG ATA GCT CCA GAG AGC ATC
Ala Tyr Lys Pro Ala Pro Gly Thr Cys Cys Tyr Ile MET Lys Ile Ala Pro Glu Ser Ile

                                               450                                                 480
CCC AGT CTT GAG GCT CTC ACT AGA AAA GTC CAC AAC TTC CAG ATG GAA TGC TCT CTG CAG
Pro Ser Leu Glu Ala Leu Thr Arg Lys Val His Asn Phe Gln MET Glu Cys Ser Leu Gln
```

FIG.5A

```
                                                                  510                                                               540
GCC AAG CCC GCA GTG CCT ACG TCT AAG CTG GGC CAG GCA GAG GGG CGA GAT GCA GGC TCA
Ala Lys Pro Ala Val Pro Thr Ser Lys Leu Gly Gln Ala Glu Gly Arg Asp Ala Gly Ser

                                                                  570                                                               600
GCA CCC TCC GGA GGG GAC CCG GCC TTC CTG GGC ATG GCC GTG AGC ACC CTG TGT GGC GAG
Ala Pro Ser Gly Gly Asp Pro Ala Phe Leu Gly MET Ala Val Ser Thr Leu Cys Gly Glu

                                                                  630                                                               660
GTG CCG CTC TAC TAC NTC TAG GAC GCC TCC GGG TCA GTG GAA GCC CCA ACG GAA AGG AAA
Val Pro Leu Tyr Tyr Ile End

                                                                  690                                                               720
CGC CCC GGG CAA AGG GTC TTT TGC AGC TTT TGC AGA CGG GCA AGA AGC TGC TTC TGC CCA

                                                                  750                                                               780
CAC CGC AGG GAC AAA CCC TGG AGA AAT GGG AGC TTG GGG AGA CGA TGG GAG TGG GCA GAG

                                                                  810                                                               840
GTG GCA CCC AGG GGC CCG GGA ACT CCT GCC ACA ACA GAA TAA AGC AGC CTG ATT TGA AAA

GCA AAA AAA AAA AAA AAA
```

FIG.5B

```
                10                  26                  41                  56
GCTGCAGAGG TGCCC ATG GCT GAG TCA CAC CTG CTG CAG TGG CTG CTG CTG CTG CCC
                 MET Ala Glu Ser His Leu Leu Gln Trp Leu Leu Leu Leu Pro
                  1

                71                  86                 101                 116
ACG CTC TGT GGC CCA GGC ACT GCT GCC TGG ACC ACC TCA TCC TTG GCC TGT GCC CAG GGC CCT GAG
Thr Leu Cys Gly Pro Gly Thr Ala Ala Trp Thr Thr Ser Ser Leu Ala Cys Ala Gln Gly Pro Glu

               131                 146                 161                 176                 191
TTC TGG TGC CAA AGC CTG GAG CAA GCA TTG CAG TGC AGA GCC CTA GGG CAT TGC CTA CAG GAA GTC
Phe Trp Cys Gln Ser Leu Glu Gln Ala Leu Gln Cys Arg Ala Leu Gly His Cys Leu Gln Glu Val
                                                    50

               206                 221                 236                 251
TGG GCA CAT GTG CGA GCC GAT GAC CTA TGC CAA CAG TGT GAG GAC ATC GTC CAC ATC CTT AAC AAG
Trp Gly His Val Gly Ala Asp Asp Leu Cys Gln Glu Cys Glu Asp Ile Val His Ile Leu Asn Lys

               266                 281                 296                 311
ATG GCC AAG GAG GCC ATT TTC CAG GAC ACG ATG AGG AAG TTC CTG GAG CAG GAG TGC AAC GTC CTC
MET Ala Lys Glu Ala Ile Phe Gln Asp Thr MET Arg Lys Phe Leu Glu Gln Glu Cys Asn Val Leu
                                                                    100

               326                 341                 356                 371                 386
CCC TTG AAG CTG CTC ATG CCC CAG TGC AAC CAA GTG CTT GAC GAC TAC TTC CCC GTG GTC ATC GAC
Pro Leu Lys Leu Leu MET Pro Gln Cys Asn Gln Val Leu Asp Asp Tyr Phe Pro Leu Val Ile Asp

               401                 416                 431                 446
TAC TTC CAG AAC CAG ACT GAC TCA AAC GGC ATC TGT ATG CAC CTG GGC CTG TGC AAA TCC CGG CAG
Tyr Phe Gln Asn Gln Thr Asp Ser Asn Gly Ile Cys MET His Leu Gly Leu Cys Lys Ser Arg Gln
```

FIG.6A

```
461                 476                 491                 506                 521
CCA GAG CCA GAG CAG GAG CCA GGG ATG TCA GAC CCC CTG CCC AAA CCT CTG CGG GAC CCT CTG CCA
Pro Glu Pro Glu Gln Glu Pro Gly MET Ser Asp Pro Leu Pro Lys Pro Leu Arg Asp Pro Leu Pro
                150

                    536                 551                 566                 581
GAC CCT CTG CTG GAC AAG CTC GTC CTC CCT GTG CTG CCC GGG GCC CTC CAG GCG AGG CCT GGG CCT
Asp Pro Leu Leu Asp Lys Leu Val Leu Pro Val Leu Pro Gly Ala Leu Gln Ala Arg Pro Gly Pro

596                 611                 626                 641
CAC ACA CAG GAT CTC TCC GAG CAG CAA TTC CCC ATT CCT CTC CCC TAT TGC TGG CTC TGC AGG GCT
His Thr Gln Asp Leu Ser Glu Gln Gln Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Cys Arg Ala
                            200

656                 671                 686                 701                 716
CTG ATC AAG CGG ATC CAA GCC ATG ATT CCC AAG GGT GCG CTA CGT GTG GCA GTG GCC CAG GTG TGC
Leu Ile Lys Arg Ile Gln Ala MET Ile Pro Lys Gly Ala Leu Arg Val Ala Val Ala Gln Val Cys

731                 746                 761                 776
CGC GTG GTA CCT CTG GTG GCG GGC GGC ATC TGC CAG TGC CTG GCT GAG CGC TAC TCC GTC ATC CTG
Arg Val Val Pro Leu Val Ala Gly Gly Ile Cys Gln Leu Ala Glu Arg Tyr Ser Val Ile Leu
                                                250

791                 806                 821                 836                 851
CTC GAC ACG CTG CTG GGC CGC ATG CTG CCC CAG CTG GTC TGC CGC CTC GTC CTC CGG TGC TCC ATG
Leu Asp Thr Leu Leu Gly Arg MET Leu Pro Gln Leu Val Cys Arg Leu Val Leu Arg Cys Ser MET

866                 881                 896                 911
GAT GAC AGC CCT CGC CCA AGG TCG CCG ACA GGA GAA TGG CTG CCG CGA GAC TCT GAG TGC CAC CTC
Asp Asp Ser Ala Gly Pro Arg Ser Pro Thr Gly Glu Trp Leu Pro Arg Asp Ser Glu Cys His Leu
                                                                    300
```

FIG.6B

SUBSTITUTE SHEET

```
      926                941                956                971
TGC ATG TCC GTG ACC ACC CAG GCC GGG AAC AGC AGC GAG CAG GCC ATA CTA CAG GCA ATG CTC CAG
Cys MET Ser Val Thr Thr Gln Ala Gly Asn Ser Ser Glu Gln Ala Ile Leu Gln Ala MET Leu Gln
                                                    350

     1001               1016               1031               1046
GCC TGT GTT GGC TCC TGG CTG GAC AGG GAA AAG TGC AAG CAA TTT GTG GAG CAG CAC ACG CCC CAG
Ala Cys Val Gly Ser Trp Leu Asp Arg Glu Lys Cys Lys Gln Phe Val Glu Gln His Thr Pro Gln

     1061               1076               1091               1106
CTG CTG ACC CTG GTG CCC AGG GGC TGG GAT GCC CAC ACC ACC TGC CAG GCC CTC GGG GTG TGT GGG
Leu Leu Thr Leu Val Pro Arg Gly Trp Asp Ala His Thr Thr Cys Gln Ala Leu Gly Val Cys Gly

     1121               1136               1151               1170               1180
ACC ATG TCC AGC CCT CTC CAG TGT ATC CAC AGC CCC GAC CTT TGA TGAGAACTCA GCTGTCCAGC
Thr MET Ser Pro Leu Gln Cys Ile His Ser Pro Asp Leu .

     1190               1200               1210               1220               1230               1240               1250               1260
TGCAAAGGAA AAGCCAAGTG AGACGGGCTC TGGGACCATG GTGACCAGGC TCTTCCCCTG CTCCCTGGCC CTCGCCAGCT

     1270               1280               1290               1300               1310               1320               1330               1340
GCCAGGCTGA AAAGAAGCCT CAGCTCCCAC ACCGCCCTCC TCACCGCCCT TCCTCGGCAG TCACTTCCAC TGGTGGACCA

     1350               1360               1370               1380               1390               1400               1410               1420
CGGGGCCCCA GCCCTGTGTC GCCCTTGTCT GTCTCAGCTC AACCACAGTC TGACACCAGA GCCCACTTCC ATCCTCTCTG

     1430               1440               1450               1460               1470               1480               1490               1500
GTGTGAGGCA CAGCGAGGGC AGCATCTGGA GGAGCTCTGC AGCCTCCACA CCTACCACGA CCTCCCAGGG CTGGGCTCAG

     1510               1520               1530               1540               1550               1560               1570               1580
GAAAAACCAG CCACTGCTTT ACAGGACAGG GGGTTGAAGC TGAGCCCCGC CTCACACCCA CCCCCATGCA CTCAAAGATT
```

FIG.6C

```
1590       1600       1610       1620       1630       1640       1650       1660
GGATTTTTACA GCTACTTGCA ATTCAAAATT CAGAAGAATA AAAAATGGGA ACATACAGAA CTCTTAAAAGA TAGACATCAG

1670       1680       1690       1700       1710       1720       1730       1740
AAATTGTTAA GTTAAAGCTTT TTCAAAAAAT CAGCAATTCC CAGCGTAGTC AAGGGTGGAC ATGCACGCGT CTGGCATGAT

1750       1760       1770       1780       1790       1800       1810       1820
GGGATGGCGA CCGGGCAAGC TTTCTTCCTC GAGATCGTCT GCTCGTTGAG AGCTATTGCT TTGTTAAGAT ATAAAAGGG

1830       1840       1850       1860       1870       1880       1890       1900
GTTTTCTTTTT GTCTTTTCTGT AAGGTGGACT TCCAGCTTTT GATTGAAAGT CCTAGGGTGA TTCTATTTCT GCTGTGATTT

1910       1920       1930       1940       1950       1960       1970       1980
ATCTGCTGAA AGCTCAGCTG GGGTTGTGCA AGCTAGGGAC CCATTCCTAT GTAATACAAT GTCTGCACCA ATGCTAATAA

1990       2000       2010
AGTCCTATTC TCTTTTTATGA GAAAAAAAAA AAAAAAA
```

FIG.6D


10th codon of pUC19 lacZ gene
SalI
EcoRI
214.1 insert
.....TGC AGG TCG ACT CTA GAG GAT CCC CGG GTA CCG AGC TCG AAT TC CGG GAG TGC.....
Cys Arg Ser Thr Leu Glu Asp Pro Arg Val Pro Ser Ser Asn Arg Glu Cys
SalI
.....TGCAGG TCGACTCTAG.....
.....ACGTCCAGCT GAGATC.....
T4 Polymerase fill-in
.....TGCAGGTCGATCGACTCTAG.....
.....ACGTCCAGCTAGCTGAGATC.....
.....TGC AGG TCG ATC GAC TCT AGA GGA TCC CCG GGT ACC GAG CTC GAA TTC CGG GAG TGC.....
Cys Arg Ser Ile Asp Ser Arg Gly Ser Pro Gly Thr Glu Leu Glu Phe Arg Glu Cys


A B C D
97-
68-
43-
26-
18-
14-

FIG.7



FIG.8a

FIG. 8B-1

```
        10          20          30          40          50          60          70
GGATCCTCCC TCCTCGGCCT CCCAAAGTGC CAGGATTACA GGAGTGAGCC ACCACACCCA GCCCCATCTC

        80          90         100         110         120         130         140
TTTTCATCAT GGTACTAATT CCTGCCCGTC CACCCACAAA AGCACTGTAG TCGTTCCCGA GTATAGAGGC

       150         160         170         180         190         200         210
CTGTGAGCCT CCACTAGGGA GAGGGCTCCT GCAGAGATCA GATAAATTGA TCACAATGGC TGGGGTGGTG

       220         230         240         250         260         270         280
GCAATGTGCT AATGCTCTCT TTCTTCCACT CAAGATATCC TCTGTCTCCC TCAGCCTGTG AGCTTTTTCT

       290         300         310         320         330         340         350
CCAGTGTGCT CTGCCAGTGG GGGCCCTGCC TGAGAGCCCC TGCAGCTGCA GAGGACAGTT TCTTTCTGCT

       360         370         380         390         400         410         420
GAACCATCGC AGCTATGCCC CAGCCCCTAC CCTGGAGGGG TCCCCAGGGG CCATGGGCAG CACCTCCTGT
```

FIG. 8B-2

```
       430        440        450        460        470        480        490
ATAGGGCTGT CTGGGAGCCA CTCCAGGGCC ACAGAAATCT TGTCTCTGAC TCAGGGTATT TTGTTTTCTG

       500        510        520        530        540        550        560
TTTTGTGTAA ATGCTCTTCT GACTAATGCA AACCATGTGT CCATAGAACC AGAAGATTTT TCCAGGGGAA

       570        580        590        600        610        620        630
AAGGTAAGGA GGTGGTGAGA GTGTCCTGGG TCTGCCCTTC CAGGGCTTGC CCTGGGTTAA GAGCCAGGCA

       640        650        660        670        680        690        700
GGAAGCTCTC AAGAGCATTG CTCAAGAGTA GAGGGGGCCT GGGAGGCCCA GGGAGGGGAT GGGAGGGGAA

       710        720        730        740        750        760        770
CACCCAGGCT GCCCCCAACC AGATGCCCTC CACCCTCCTC AACCTCCCTC CCACGGCCTG GAGAGGTGGG

       780        790        800        810        820        830        840
ACCAGGTATG GAGGCTTGAG AGCCCCTGGT TGGAGGAAGC CACAAGTCCA GGAACATGGG AGTCTGGGCA

       850        860        870        880        890        900        910
GGGGGCAAAG GAGGCAGGAA CAGGCCATCA GCCAGGACAG GTGGTAAGGC AGGCAGGAGT GTTCCTGCTG
```

FIG. 8B-3

```
      920        930        940        950        960        970        980
GGAAAAGGTG GGATCAAGCA CCTGGAGGGC TCTTCAGAGC AAAGACAAAC ACTGAGGTCG CTGCCACTCC

      990       1000       1010       1020       1030       1040       1050
TACAGAGCCC CCACGCCCCG CCCAGCTATA AGGGGCCATG CCCCAAGCAG GGTACCCAGG CTGCAGAGGT

                1068                  1083                  1098
GCC ATG GCT GAG TCA CAC CTG CTG CAG TGG CTG CTG CTG CTG CTG CCC ACG CTC
    MET Ala Glu Ser His Leu Leu Gln Trp Leu Leu Leu Leu Leu Pro Thr Leu

      1113                  1130       1140       1150       1160       1170
TGT GGC CCA GGC ACT G GTGAGTCTCC CCCAGCCTCC CCTCTCCTAG GCAGCTCCAC CACTCACTGA
Cys Gly Pro Gly Thr A

      1180       1190       1200       1210       1220       1230       1240
GCACTGCTTT GTGCTAGGCA TTAACCCAAG TCTGTCCTCA TTTTAAAGAC AAGGCAGCTG GGGTTCAGAG

      1250       1260       1270       1280       1290       1300       1310
AGGGTTCAGA GCTTATCCAA GGTCACACAG CTGGCGGGTC CAGGAGCAGG TGGAACCCAG  AGCTGTCTGA

      1320       1330       1340       1350       1360       1370       1380
CGTCCACATG TTTAATGGCC TCACACTCCC AGCAAAACTG GGTCTAGAGG GTGGGTGAAA TCATGATGCC
```

FIG. 8B-4

```
      1390        1400        1410        1420        1430
AGGTGTGTAG CCTGGATCCT GATTAAGGTT GCTCTGGCCC CAAACCACAG  CT GCC TGG ACC
                                                        la Ala Trp Thr

1444                 1459                1474                1489
ACC TCA TCC TTG GCC TGT GCC CAG GGC CCT GAG TTC TGG TGC CAA AGC CTG GAG
Thr Ser Ser Leu Ala Cys Ala Gln Gly Pro Glu Phe Trp Cys Gln Ser Leu Glu

       1504                1519                1534                1549
CAA GCA TTG CAG TGC AGA GCC CTA GGG CAT TGC CTA CAG GAA GTC TGG GGA CAT
Gln Ala Leu Gln Cys Arg Ala Leu Gly His Cys Leu Gln Glu Val Trp Gly His

                    1568        1578        1588        1598        1608        1618
GTG GGA GCC GTGAGTACCA CCAAGGATGC ATGGCAACTG GGGGTCTGAA ATGAAGGGTG CTGGGTGGGC
Val Gly Ala

      1628        1638        1648        1658        1668        1678        1688
TCTGGATGGG CAGGAGGAGA GTGGAGCCCC CATAGGGGAT GGATGAGATG AAATGGGATG AGATGAAATG

      1698        1708        1718        1728        1738        1748        1758
AGATAGGATA AAATGGAATG GGATGGATGC GATGGGATAC GATGACATAG AATAGATGGA GTCGGATGAA
```

FIG. 8B-5

```
      1768        1778        1788        1798        1808        1818        1828
TGGGATGGGA TGGGATGGAT GGGAGGGGAA GGGATAGGAT AGGATGACAT AGAATAAAGA TGGATGGGAT

      1838        1848        1858        1868        1878        1888        1898
GGGATGGGAT GGGATGGGAT GACACAGAAT AAAGATGGAT GGATTGGGAT GGATGAATAG AAGAGATGGA

      1908        1918        1928        1938        1948        1958        1968
TGGGATAAAT TGATATGGAT GAGATGGGAC AAGTTGGGCT GGTGGGCAGC TGCATGTGCC TTGGAGTGCT

      1978        1988        1998        2008        2018        2028        2038
CTGTTGGCCT CTTCCTAAGA GAACCTCCCC ATTGGAGCTG GGAGCCTCCC CCACTCATGT GTCCTCCACC

      2048        2058                    2074                    2089
TTGGGGCCCC TCCCTCCCCA G GAT GAC CTA TGC CAA GAG TGT GAG GAC ATC GTC CAC
                        Asp Asp Leu Cys Gln Glu Cys Glu Asp Ile Val His

      2104                2119                            2141        2151
ATC CTT AAC AAG ATG GCC AAG GAG GCC ATT TTC CAG GTAATGATGC CCAGATCCTG
Ile Leu Asn Lys MET Ala Lys Glu Ala Ile Phe Gln

      2161        2171        2181        2191        2201        2211        2221
GATGAAGGTT GGGGCCCAAG AGATGAGGGA CAGAGCAGGG AAGAGCTGAG CCCCCTAAAG GGGCCATTTC
```

FIG. 8B-6

```
      2231        2241        2251        2261        2271        2281        2291
CAGGCTGAGG AGGAGGCCTG GGTGCCTGGG AAGTCCCAGC TCCTCCTGGC TGGGAGCAGG TCATGGCCCT

      2301        2311        2321        2331        2341        2351        2361
GAGCTCAATA GCACAGCCAG AGATGGTCTT CCCTGAGGGG AAGGGCCCCT ACATGTGCCC AACTACTTAA

      2371        2381        2391        2401        2411        2421        2431
CTCCTTGGCA CTCGTGAACT CCAGCACCCT GGGGGATTAG GGGTCAGTCT GCCCTGGTGG GGCCTTGTGT

      2441        2451        2461        2471        2481        2491
CCAGGGACTT GGGCGGGGTA GACCTCAGAG AGGCCCAGCT GACGGCCCCC TCTGGCCTCC CAG

                  2509                    2524                    2539
GAC ACG ATG AGG AAG TTC CTG GAG CAG GAG TGC AAC GTC CTC CCC TTG AAG CTG
Asp Thr MET Arg Lys Phe Leu Glu Gln Glu Cys Asn Val Leu Pro Leu Lys Leu

    2554                    2569                    2584                    2599
CTC ATG CCC CAG TGC AAC CAA GTG CTT GAC GAC TAC TTC CCC CTG GTC ATC GAC
Leu MET Pro Gln Cys Asn Gln Val Leu Asp Asp Tyr Phe Pro Leu Val Ile Asp
```

FIG. 8B-7

```
          2614                2630       2640       2650       2660       267
TAC TTC CAG AAC CAG ATT GTGAGGGCTG CAAGCTCACC TCCTGCCTGC CTCCCCACGC AGGCCCCTG
Tyr Phe Gln Asn Gln Ile

     2680       2690       2700       2710       2720       2730       2740
GCCCACCCAT GGGGGAGCCA CACACACAGC ACCCCAGCCA GCCAGACACA CACACACACA CACACACACA

     2750       2760       2770       2780       2790       2800       2810
CAGCACCCAA GCCGGCCAGA CACAAACACA CAGCACCCCA GCCAGCCGGA CACACACACA CACACACACA

     2820       2830       2840       2850       2860       2870       2880
CACAACACCC CAGCTGGCCG GACACACACA CACACAGTAC CCCAGCTGGC CGGACACACA CACACACAGC

     2890       2900       2910       2920       2930       2940       2950
ACCCTATCCA GACACATACA CACACACAGT ACCCCAGCCA GCTGGAAACA CACACACACA CAGCACTCCA

     2960       2970       2980       2990       3000       3010       3020
TCCAGACACA TACCCACACA GTACCCCAGC CAGCCAGACA CACACACACA CACACACACA CACACACACA

     3030       3040       3050       3060       3070       3080       3090
CAGAGCACAC ACACAGCACC CCAGCTGGCC ACACACACAC ACACACACAC CCTGTCCACA AAGGGCCTAG
```

FIG. 8B-8

```
      3100        3110        3120        3130        3140        3150        3160
GAAACTACGT GCCCTTCAGC CATGCACCCG ACCATGGGCC CCCAGGTTCA GGTGCACACG GTGGGCCTGT

      3170        3180        3190        3200        3210        3220        3230
ACGCTCACAC ACCCTTACAC CCTCACTCTC ACACACATGC TTACACACTT ATTCATTCTC ACATATATGC

      3240        3250        3260        3270        3280        3290        3300
TCATGCTCAT TCACACACAA TCCCGGGCCA CCTGCCCTAA AGTCCCCACA CAGCCCTATC TTTGCCTTTT

      3310        3320        3330        3340        3350        3360        3370
GTCCCCCCAC ATAGAGTTCT AAACCACAGC ACCCCCACTA GGCCTGCTTC CTCCCATTCC AGTGGTCCCT

      3380        3390        3400        3410        3420        3430        3440
GAGCCCTTGG GCCGGCCTGA ATAGGGGTGG GCTTCCCTCC CAGACCCTAA CACTCCCACC CTGTGCTGTG

                          3461                3476                3491
CCCCAG GAC TCA AAC GGC ATC TGT ATG CAC CTG GGC CTG TGC AAA TCC CGG CAG
       Asp Ser Asn Gly Ile Cys MET His Leu Gly Leu Cys Lys Ser Arg Gln
```

FIG. 8B-9

```
                3506                    3521                    3536
CCA GAG CCA GAG CAG GAG CCA GGG ATG TCA GAC CCC CTG CCC AAA CCT CTG CGG
Pro Glu Pro Glu Gln Glu Pro Gly MET Ser Asp Pro Leu Pro Lys Pro Leu Arg

3551                    3566                    3581                    3596
GAC CCT CTG CCA GAC CCT CTG CTG GAC AAG CTC GTC CTC CCT GTG CTG CCC GGG
Asp Pro Leu Pro Asp Pro Leu Leu Asp Lys Leu Val Leu Pro Val Leu Pro Gly

          3611                    3626                    3645        3655        3665
GCC CTC CAG GCG AGG CCT GGG CCT CAC ACA CAG GTGAGGGAGG CCCCCACAGC CAGTAAAGTG
Ala Leu Gln Ala Arg Pro Gly Pro His Thr Gln

      3675        3685        3695        3705        3715        3725        3735
GAGATCCAGA GGGCTAGAGC CACCTCCGAA GCCCATGGGC ACTGGGCCCT GGGAGAGGCA GAGCCGGGAA

      3745        3755        3765        3775        3785        3795        3805
GGTGATAGGA AGCTCCAGGC AGGGCCTAAG GGAGGAGGGA GAGAAAGGGA GGAAGAGAGA GGGGAGGAGA

      3815        3825        3835        3845        3855
GCCTGGAGGA CTCTTCTCCC AGCACCCAGC CTGGCCTCCA CCTGATTCTT TCCCCAG GAT CTC
                                                              Asp Leu
```

FIG. 8B-10

```
      3877                3892                3907                3922
TCC GAG CAG CAA TTC CCC ATT CCT CTC CCC TAT TGC TGG CTC TGC AGG GCT CTG
Ser Glu Gln Gln Phe Pro Ile Pro Leu Pro Tyr Cys Trp Leu Cys Arg Ala Leu

               3937                3952       3962       3972       3982
ATC AAG CGG ATC CAA GCC ATG ATT CCC AAG GTGAGGCATC CAGGGCCTCA AGAGCCCAGG
Ile Lys Arg Ile Gln Ala MET Ile Pro Lys

      3992       4002       4012       4022       4032       4042       4052
AGCACACGCA TACCTGTAGC TCCCTGCAGC TCCCACCTCT CTCCCAACTC ACACCCCCGT CAGACCCAGC

      4062       4072       4082       4092       4102       4112       4122
TGGCTGCCAG AAGTTAGGAG GGGAGAGAGC CGCTTGTGCA TTGCCCCCAC CCAGGGACCC TGGGCTCAGG

      4132       4142       4152       4162       4172       4182       4192
CTCAGGCCTG GTAGGTGCCA GGTACAGTTC ATGCAACAAA CATTAAGCCC CCACTGTATG GAGGTGCCAG

      4202       4212       4222       4232       4242       4252       4262
CCAGGAGCCA AAGTACAAAA ACGGACAAGA CGCAGCTTTG TCCTCCAGCA GCTCACCATC TGATGGAGAA

      4272       4282       4292       4302       4312       4322       4332
AGATCCCCAG AGGTCTCTGT AGAAAGGTTG CTTTGATCTT TCAAGAGGGG AATTTCCACA GATAGATTCC
```

FIG. 8B-11

```
      4342       4352       4362       4372       4382       4392       4402
CCATCCTTGC CTGAGTCCAA CTTGGAGTCT TCCAGACCTG CAGTGGCTAT TGTCCAATGG CCCCGCCAGC

      4412       4422       4432       4442       4452       4462       4472
CCAGGGCTAC CTTGCCCAAA TTGGGGCCCA AATGAGGAAA GGCCCTGCCC CCTCAGCCTT TCCCAGATTG

      4482       4492       4502       4512       4522       4532       4542
GGTTGCGTGG GCCACCAGGG GCACAAGGCA GCAGGTGAGG TTCCTGCTGA GGCAGGTGGT TCACTTGAGC

      4552       4562       4572       4582       4592       4602       4612
CCAGGAGTTC AAGACCAGCT TGGGCAACAT GGCGAAACCC CGTCTCTACT AAGAATACAA AAATTAGCCA

      4622       4632       4642       4652       4662       4672       4682
GATGTGACAG GTGCCTGTAG TCCCAGCTAC TCGGGAGGCT GAGGCAGGAG AATCACTTGA ACCCAGGAGG

      4692       4702       4712       4722       4732       4742       4752
CGGAGGTTGC AGTGAGCCGA CATCACGCCA CTGTACTCTA GCCTGGGTGA CAGAGCAAGA CTCTGTCTCA
```

FIG. 8B-12

```
4762        4772        4782        4792        4802        4812        4822
AAAAAAAAGA AAGAAGGAAA GATCACTGCA GAGATTGCAG TGAGAGGTGA TGGGACAGGG ACGGAGCTGA

4832        4842        4852        4862        4872        4882        4892
GGGCTGGCCT GGGGATGCAT TTGGGAGGTG GGCCCACTGC TATGGGCATG GATGGGCCTG GAGCGTGAGG

4902        4912        4922        4932        4942        4952        4962
ACCAGGGAGG ACTCCAAAGT GACTTTTACA CACTGGCCAG AGCAACCAGC CCTCTGTAAT GCCAGCAGCT

4972        4982        4992        5002        5012        5022        5032
GAGATGGGGA GACTAAAGAA GAAAACAGGT TTGAGCAAAA AAACAGAGAG CTCCCTCCTG GCCATGTTGA

5042        5052        5062        5072        5082        5092        5102
GTTCAAGATG CCTGTGTGAA GTGCAGGAGA GGAGAGTCAG GCAAGCAGCT GAATCCCAAG CATTGGGGGA

5112        5122        5132        5142        5152        5162        5172
AGGTCAGGTC CACCATGTCA GTCTGAGAGT CACTAGCTGT GGGCCAGAGC CTTTGGGGCC AGACGTAGGT

5182        5192        5202        5212        5222        5232        5242
CTGAAGCTGG CTCCTACACT CAGTGACCCT GTGTGAGTCC CCTGCATCCC CTGGACTCTC TGATCCCCAG
```


PCT/US87/02536

FIG. 8B-13

```
      5252        5262        5272        5282        5292        5302        5312
TGTCCTTATT TGTGAATAGC CTTGCCCTCC CTTCTAGAAG AGAATGAGGG AATGCGTAGG AAGTGCCCAG

      5322        5332        5342        5352        5362        5372        5382
CTGGGTGCTG GGCAGAGAGT GGAGGCTTGC CAAGTGAAGG TCCCATGCTG GCCTCTCTCC GCCCCCGCCC

                          5400                    5415                    5430
CAG GGT GCG CTA CGT GTG GCA GTG GCC CAG GTG TGC CGC GTG GTA CCT CTG GTG
    Gly Ala Leu Arg Val Ala Val Ala Gln Val Cys Arg Val Val Pro Leu Val

       5445                    5460                    5475                    5490
GCG GGC GGC ATC TGC CAG TGC CTG GCT GAG CGC TAC TCC GTC ATC CTG CTC GAC
Ala Gly Gly Ile Cys Gln Cys Leu Ala Glu Arg Tyr Ser Val Ile Leu Leu Asp

                    5505                    5520                    5535
ACG CTG CTG GGC CGC ATG CTG CCC CAG CTG GTC TGC CGC CTC GTC CTC CGG TGC
Thr Leu Leu Gly Arg MET Leu Pro Gln Leu Val Cys Arg Leu Val Leu Arg Cys

   5550                    5565                    5578        5588        5598        5608
TCC ATG GAT GAC AGC GCT GGC CCA A GTGAGCCCA CTGCCCCCTC CTTAGCCCAA TGCCCGCTCT
Ser MET Asp Asp Ser Ala Gly Pro A
```

FIG. 8B-14

```
      5618        5628        5638        5648        5658        5668        5678
CCTCCTCCCC CTACCCTGCC ACTGCATGAC CCTCTCCCTC TGTGGTCCCA CTGCAATGCA CCAAGGAGGA

      5688        5698        5708        5718        5728        5738
CAGAAACCAA ACACCTCTGT AGGGTGGCCT TGCCTGCTTT CCCCCTAATG CTCACATCTC CAG GG
                                                                    rg

            5755                    5770                    5785
TCG CCG ACA GGA GAA TGG CTG CCG CGA GAC TCT GAG TGC CAC CTC TGC ATG TCC
Ser Pro Thr Gly Glu Trp Leu Pro Arg Asp Ser Glu Cys His Leu Cys MET Ser

5800                5815                    5830                5845
GTG ACC ACC CAG GCC GGG AAC AGC AGC GAG CAG GCC ATA CCA CAG GCA ATG CTC
Val Thr Thr Gln Ala Gly Asn Ser Ser Glu Gln Ala Ile Pro Gln Ala MET Leu

       5860                5875                            5897        5907
CAG GCC TGT GTT GGC TCC TGG CTG GAC AGG GAA AAG GTATGGGCTG GGCACATGGG
Gln Ala Cys Val Gly Ser Trp Leu Asp Arg Glu Lys

      5917        5927        5937        5947        5957        5967        5977
GACTCATGGT CAGGGCCCGT TCAAGGCAGA AGGCTGAGCC CAGGAAAGGC TTTGCAGCCA GAGACACCTA

      5987        5997        6007        6017        6027        6037        6047
GGATGGGCCA GAATGGAGCA CAGACAGGCA GACAGGATGT GGGGCAGACA ATGGTGGGAC TGTAAGTTAG
```

FIG. 8B-15

```
      6057       6067       6077       6087       6097       6107       6117
GGCAGAGCCT GCTAAGGGTT AGGAGTCGCC TCTGGACAAA GGGCTGTGGG CTCCAGAGGA CCAGCAGGCC

      6127       6137       6147       6157       6167       6177       6187
CTCTTCACGG GCTGAGTGAG CACCAGGCAA GCCTTCAGAG GCCTGGTTAT CTACCAGGAG ATGAGTAATG

      6197       6207       6217       6227       6237       6247       6257
CTAGGGCCAG TTCAAGCCAG GAAAGGGACT AGCCTTCTCT CCAGGGTCCT GATCCCTTTA CTGCCCCCAC

      6267       6277       6287       6297       6307       6317       6327
ACTCCTCAAG GTGTGACTCA CTCAGGACAA ACCCATTGGC AAAAGGAGAG GGCTGGACTT GAAGGTCCTA

      6337       6347       6357       6367       6377       6387       6397
GGGCCCTTGC CAATACTCAG TCAATGACAG GAAATTCCCT TTTTTTTTTT TTTTTTTTTT TTTTTGAGAT

      6407       6417       6427       6437       6447       6457       6467
GGAGTTTTGC TCTTGTTGCC CAGGCTGGAG TGCAATGGCA CAATCTTGGC TCACTGCAAC CTCTGCCTCC
```

FIG. 8B-16

```
     6477       6487       6497       6507       6517       6527       6537
GGGTTCAGGC GATTCTCCTG CCTCAGCCTC TTGAGTAGCT GGGATTACAG GCATGTGCTA CCAGGCCCGG

     6547       6557       6567       6577       6587       6597       6607
CTAATTTTTG TATTTTTAGT AGAGACAAGG TTTCACCATA TTGGTCAGGC TGGTCTCGAA CCCCTGACCT

     6617       6627       6637       6647       6657       6667       6677
GAAGTGATCT GCCCGCCTTG GCCTCCCAAA GTGCTGGGAT TACAGGCATA AGCCACTGCA CCCGGACAGG

     6687       6697       6707       6717       6727       6737       6747
AAATTCCCTT CTTAAAGCGA GATCCTGTCC TGAGGAAAGC CAGCTGATGC TCTTCCCAGG AGGCAGCTGT

     6757       6767       6777       6787       6797       6807       6817
CCACACTGTG CTCCCTGCTC AGCAACTCCC AAGCCTCCCG ACTGCCCATC ACATCTGGTC TCAAGGACCA

     6827       6837       6847       6857       6867       6877       6887
GATGAACGTT AAGGTTCCTT CTAGAACTGA AATGGAGGTG GAGGGAGGGG AGGGTGGTGG CTGAGATTCC

     6897       6907       6917       6927       6937       6947       6957
ACCCCTCTGC CTGAGTCCTC CGTCTCCAGT GTCGCCTGCT TTTCTGATGG AAGTCCTCCA TTTCAGCCTG
```

FIG. 8B-17

```
      6967        6977        6987        6997        7007        7017        7027
GCTCCAGTTT GTTAAGGGTT TCAACTGCAG CCAGAGGTGT TCCGTGAGGG CTGATGGAGG AGTCGGGAGG

      7037        7047        7057        7067        7077        7087        7097
GAGCCCTAGA GTGATCCAGA GATGTGGAGA GGCCCAGGAC CACACGACAG GAGAGTCCTG CAAAGGGACC

      7107        7117                    7136                    7151
TCCACAGCTG TGTGTCTCCC TCAG TGC AAG CAA TTT GTG GAG CAG CAC ACG CCC CAG
                          Cys Lys Gln Phe Val Glu Gln His Thr Pro Gln

            7166                7181                7196                7212
CTG CTG ACC CTG GTG CCC AGG GGC TGG GAT GCC CAC ACC ACC TGC CAG GTACACCCAA
Leu Leu Thr Leu Val Pro Arg Gly Trp Asp Ala His Thr Thr Cys Gln

      7222        7232        7242        7252        7262        7272        7282
CCCCTCCCAA GTTGGTCCTA GGACTTCCCT TGGCTCCCAG AGCCCCCACC CTTTGGGCCC GTGATCCTCA

      7292        7302        7312        7322        7332        7342        7352
GAGGCCTCAC TCCCCTGGGT CCAAGGTGGT CCCAGGTGCA CGGGCCAGGG ACTGGGAGGC ACCCCTCTCT
```

FIG. 8B-18

```
      7362        7372        7382        7392        7402        7412        7422
GTTTCAGTGT AAAAAATCAT GAGAGCATGG AAAAGGGGGA TGGGAAGGGA GGGATGGCCT GAGGAGTGCG

      7432        7442        7452        7462        7472        7482        7492
GCTGGATGTC CATTATAGGA TGGGGCTGTG TTCCCTGGCC AGTGTGTGCT GGTGGGGTGG GGGTACAAAG

      7502        7512        7522        7532        7542        7552        7562
TGGGTGTTCT GGAGTGAACA TCTCACCTCC TCAGGCTCTA AACCCTAAGG CCTGTGGCTC AGGGAGTGGC

      7572        7582        7592        7602        7612        7622        7632
CGAGGGGTCT ACAGAGTCAC ACTGGTAGCA CCCACTAGGC GGGAGGTGGA GTGAGTGCTG TTCTTTCCCG

      7642        7652        7662        7672        7682        7692
GAAGAGCTGG GTGTGGGGAG CTGAGGGGGC CCAGGCCTCA GCCCTGGTGC TGTCCCTGTG ACAG

                  7711                    7726                    7741
GCC CTC GGG GTG TGT GGG ACC ATG TCC AGC CCT CTC CAG TGT ATC CAC AGC CCC
Ala Leu Gly Val Cys Gly Thr MET Ser Ser Pro Leu Gln Cys Ile His Ser Pro

   7756        7769        7779        7789        7799        7809        7819
GAC CTT TGA TGAGAACTCA GCTGTCCAGG TGAGTCCAGG CCCCCAGTTG CGGGGAGGTA AGGGGGCAGG
Asp Leu
```

FIG. 8B-19

```
      7829        7839        7849        7859        7869        7879        7889
TCCTGACCAT CAGGGCATGG GAGGCCCTTC TGCTCCCCAA GCAGGAAGAG GCGGCCACTC CTGCCGGCTG

      7899        7909        7919        7929        7939        7949        7959
CTCCATCCTC CCTCTCACCG CACAGCTGGA GGCTCCTGAG GGCTTCTGGC TGGCCATCAG GAAAACACCC

      7969        7979        7989        7999        8009        8019        8029
TTTCCGGACC CCGAGCACTG CCCCGCCCAG AACCCCAGTC ACTGAGTGCC CAACCCCCAG CTTCCCCCCC

      8039        8049        8059        8069        8079        8089        8099
AACCCCCCGC CCTGCCCTGT CCCAGGCCTC CCTCTCAGAG CTTGCCCCAG GGACTCTCTG GCCCTCAGGG

      8109        8119        8129        8139        8149        8159        8169
TTCAATGTAT TCTGACCAAG GCCAAGCTTT CCTGGGGCTC AGGGAAAATC ACACTTTGCT ACCCGAAGCT

      8179        8189        8199        8209        8219        8229        8239
GTATCCCCTC AGATGCCAGG AAGGCCGTGA TCATCTGACT CCACCCTCCT GAGACACATT CTCTCCCTGA
```

FIG. 8B-20

```
      8249        8259        8269        8279        8289        8299        8309
CTGTCCTGTT CTAAGTCAGC GGAGCACCTT AGGATGGAGG GGTGGAGGCG AGGCCAGATG CAGCCTCTGT

      8319        8329        8339        8349        8359        8369        8379
GAACAGGTGC CTGGAGGCTG GGAAATGACC CTGAGAGGGC AGGACACAGC AACCGTGGGC TTAAGGTGAC

      8389        8399        8409        8419        8429        8439        8449
CTTGAGAGCA AGCTTGGCCC ACTTTACAAT TCTGTTCAGA GCCAGCCCCT AACATGGTGG TCATTTATTC

      8459        8469        8479        8489        8499        8509        8519
ATTTGTTCCC TCATTTTAAA AAATGTAAGG CCAGGCATGG TGGCTCACGC CGGTAATCCC AGCACTTTGG

      8529        8539        8549        8559        8569        8579        8589
GAGGCCGAGG CAGGCAGATC ACCTGAGGTC AGGAGTTCGA GACTAGCCTG GCCAACATGG CGAAACCCTG

      8599        8609        8619        8629        8639        8649        8659
TCTCTACTAA AAATATTTTT TAAAAATTAG CTGAGCATGG TGGCAGGTGC CTGTAATCCC AGCTACTCAG

      8669        8679        8689        8699        8709        8719        8729
GACGCTTAGG CAGGAGAATC ACTTGAACCT GGGAGGCGAA GGTTGCGGTG TGCTGAGATC GTGCCACTGC
```

FIG. 8B-21

```
      8739       8749       8759       8769       8779       8789       8799
ACTCTAGCCT AGGCAACAGA GCACAACTCT GTCTCAGGAA AAAAAAAAAA AAAAAAAAAG GTATTTCTTT

      8809       8819       8829       8839       8849       8859       8869
GCTGGGCGCA GTGGCTCACA CCTGTAATCC CAGCACTTTG GGAGACCGAG GCGAGTGGAT CACTTGAGGT

      8879       8889       8899       8909       8919       8929       8939
CAGGAGTTCA AGACCAGCCT TACCAACATG ATGAAACCCC GTATCTACTA AAAAAAAAAA AAAAAAAAAA

      8949       8959       8969       8979       8989       8999       9009
AAAAAAATTA GCCAGATGTG GTGGCACACA CCTGTAATCC CAGCTACTTG GGAGGCTGAG GAGGAGAATT

      9019       9029       9039       9049       9059       9069       9079
GCTTGAACCT GGGAGGCGGA GATTGCAGCG AGCCAAGATT GCGCCTCTGC ACTCCAGCCT GGGTGACAGA

      9089       9099       9109       9119       9129       9139       9149
GTGAGACTCC GTCTCAAAAA AAAAAAAAAA AAAGTAGTGG GTGCCTGTGG CCAGGCCACA TCCTAGGGTA
```

FIG. 8B-22

```
      9159       9169       9179       9189       9199       9209       9219
GGGGCTATGG CTGAGCCCTG CCCTCCTGGA GCTCACAGCC AAGTCCACTT CTTCCATCTG AGGCGGGGAA

      9229       9239       9249       9259       9269       9279       9289
GCCAGCCCTG TTCCTGAAAC CCTGCATCAC AAGCCCCTGT GGGAGGCAGT GGGGAGGGGA GGTCCTCCCC

      9299       9309       9319       9329       9339       9349       9359
CACTCAGACC TGACCCACAG GGACCAGTTT AATGTGTCCT TGCCCCAGTG ATGACAGCTG GGGATCTGGG

      9369       9379       9389       9399       9409       9419       9429
GGTGGGGAGT CACCCAGGAC CCGGGCAGTC GCCTTTCCCC AGCTCCTAGG GCTCCCGGCC TTCCCTGCTG

      9439       9449       9459       9469       9479       9489       9499
AAACAGCAAG ACCAGTGGGT TGGCGTGGGA GGCCTGGGCT TCAAACCACC TCTGCTATCA CCTGGCTGTG

      9509       9519       9529       9539       9549       9559       9569
GGTCCCCAGG CAGGACATAC ACACAGTCCC TCTCTGGCCC TCATCCTCCT CAGCTGCAAA GGAAAAGCCA

      9579       9589       9599       9609       9619       9629       9639
AGTGAGACGG GCTCTGGGAC CATGGTGACC AGGCTCTTCC CCTGCTCCCT GGCCCTCGCC AGCTGCCAGG
```

FIG. 8B-23

```
      9649       9659       9669       9679       9689       9699       9709
CTGAAAAGAA GCCTCAGCTC CCACACCGCC CTCCTCACCG CCCTTCCTCG GGAGTCACTT CCACTGGTGG

      9719       9729       9739       9749       9759       9769       9779
ACCACGGGCC CCCAGCCCTG TGTCGGCCTT GTCTGTCTCA GCTCAACCAC AGTCTGACAC CAGAGCCCAC

      9789       9799       9809       9819       9829       9839       9849
TTCCATCCTC TCTGGTGTGA GGCACAGCGA GGGCAGCATC TGGAGGAGCT CTGCAGCCTC CACACCTACC

      9859       9869       9879       9889       9899       9909       9919
ACGACCTCCC AGGGCTGGGC TCAGGAAAAA CCAGCCACTG CTTTACAGGA CAGGGGGTTG AAGCTGAGCC

      9929       9939       9949       9959       9969       9979       9989
CCGCCTCACA CCCACCCCCA TGCACTCAAA GATTGGATTT TACAGCTACT TGCAATTCAA AATTCAGAAG

      9999      10009      10019      10029      10039      10049      10059
AATAAAAAAT GGGAACATAC AGAACTCTAA AAGATAGACA TCAGAAATTG TTAAGTTAAG CTTTTTCAAA
```

FIG. 8B-24

```
    10069      10079      10089      10099      10109      10119      10129
AAATCAGCAA TTCCCCAGCG TAGTCAAGGG TGGACACTGC ACGCTCTGGC ATGATGGGAT GGCGACCGGG

    10139      10149      10159      10169      10179      10189      10199
CAAGCTTTCT TCCTCGAGAT GCTCTGCTGC TTGAGAGCTA TTGCTTTGTT AAGATATAAA AAGGGGTTTC

    10209      10219      10229      10239      10249      10259      10269
TTTTTGTCTT TCTGTAAGGT GGACTTCCAG CTTTTGATTG AAAGTCCTAG GGTGATTCTA TTTCTGCTGT

    10279      10289      10299      10309      10319      10329      10339
GATTTATCTG CTGAAAGCTC AGCTGGGGTT GTGCAAGCTA GGGACCCATT CCTGTGTAAT ACAATGTCTG

    10349      10359      10369      10379      10389      10399      10409
CACCAGTGCT AATAAAGTCC TATTCTCTTT TATGAGAAAG AAAAAGACAC CAGTCCTTTA AAGTGCTGCA

    10419      10429      10439      10449      10459      10469
GTATGGCCAG ACGTGGTGGC TCACACCTGC AATCCCAGCA CCTTAGGAGG CCGAGGCAGG AGGATCC
```


0 2 4 6 8 10 12 14 16 18 20 kb
VG 519
VG 524
H S H
K
S Ap
H K
Sl
E
B
Ap H
E
H
S
K
S Ap
H K
S
Ap
H
TATAA
aataaa
1 2 3 4 5 6

FIG.9

GGTACCAGATATGTGGGAGGAGGCAAGGTAAGGGAAAGAGTACTTGAAGTTGGAACTGGTCCTTGCAGGGAAATGCACATTTATGAAACCCC -499
GAAAACTGATGTCAAAGCACCTCCTGCCTTGGGCAGTCCTCTCAGAGTCTACAGGTGCTGCCTCCAGAACCCTCTTCCTGGAGCGCATCCCT -407
ATGTATCTAGAAATTCTGCTGGGAAATATGATGGTCAGACCCTTGGCCACCTGAAAGTTCAGGGTGGTAGAAGAAAAAGGAAAGCCACAGGG -315
CAGCAGGGGCAGGTGCAGCAAGGAAGGCAGGCACGCCAGGAAGACACCCATGGGTAGAAGTGCAGATGGCCCGAGGGCACAGTTTGCTCAAC -223
TCACCCAGGTTTGCTCTTGCTGGGGCCAAGAGGACTCATGTGCCAGGGCCAAGGGCTCTGGGGGCTCTCACAGGGGGCTTATCTGGGCTTCG -131
GTTCTGGAGGGCCAGGAACAAACAGGCTTCAAAGCAAGGGCTTGGCTGGCACACAGGGGCTTGGTCCTTCACCTCTGTCCCTCTCCTACGGA -39
CACATATAAGACCCTGGTCACACCTGGGAGAGGAGGAGAGGAGAGCATAGCACCTGCAGCAAGATGGATGTGGGCAGCAAAGAGGTCCTG 52
MetAspValGlySerLysGluValLeu
ATGGAGAGCCCGCCGGTGAGTGTGGTTGCGTGTGTGTATGTATGTGCGCGCGCACATGTGTGTGATGGCCCTGCCTCCTCTATCCTCCCTGG 144
MetGluSerProPro
CCTGTTTCCTTATCCAGATCCATTCACTCAACTAACCTAGGACTGTGATAAGTCAGGATGGGGACACCAAGACCACTAAGCCAGGGACCCTT 236

FIG.10A

```
                                  *  A
GGGGAGCTGTTTGTGGCCAAGAGCCACTATAGGGGTCCGTAGAACTGGAGTGCGCGTAGACAGCCCTGAGTCAGAAGCCATGAGAAACTTCA      328

                                                                  *
GAAGTCAGGGGACACTTCTCAGAGAAAAACCACATACGAGCTGGAGCCAGAATAAGGAGGAGCTCGCCCGGTGGAGAAGGAGGAAGGCATTC      420

                                                                  *
CAGGAAGGAGGGAGACTCTGTATCACCGCATGGAGGTGATCACTTGGGGAGAGAGAGGGGCTGACCATGGCTGGGGGAAGCAGCAGGGAGAG      512

                                  *
ACAGGTGAAGCAGGCTCTCTTGGGTCCCTCAAAACTAGACCCTGCTTCTAAGCTTCTATGTATCTATGGGTTTGTTAGAATCCAGGCCACCT      604

CCTCCAAGAAGCCTTCTCTGATCTCCTCAGCCCTTCCCTGTCCATCCATCGCATCGGCTGTCCAGCCTAGGAGCCGTGGGAGGGTGTTCAGC      696

TTGTATAGGGAGAAGAGGGGACAGCCTCATGACCTCATGCCTGTCTCCTTGCCTGCCCCACCGTGTCAGGACTACTCCGCAGCTCCCCGG      786
                                                                  AspTyrSerAlaAlaProArg

GGCCGATTTGGCATTCCCTGCTGCCCAGTGCACCTGAAACGCCTTCTTATCGTGGTGGTGGTGGTGGTCCTCATCGTCGTGGTGATTGTG      876
GlyArgPheGlyIleProCysCysProValHisLeuLysArgLeuLeuIleValValValValValValLeuIleValValValIleVal

GGAGCCCTGCTCATGGGTCTCCACATGAGCCAGAAACACACGGAGATGGTGAGAGGTGTGGGATGCACAGCAGTGGGCACAGGACATGCC      966
GlyAlaLeuLeuMetGlyLeuHisMetSerGlnLysHisThrGluMet
```

FIG.10B

```
AGACAGAGGGGCTAGGTGGGATGGGCGATAGGAAACTGTCCAAGGGGAGTGGAGGGGAGGCAAGGGGCACAGCTAGAAGGAAAGAGG      1056

CACGAACCAGGCAGCAACCCAGCTCAGGCTTTTCCACAAGGCCCCTGCCCGGACAGGACAGCCAGCTCCCTCCAGCACCTGGTTCCACT      1146

CAGCCTCCCTGAACTCTTGGGAAAGAGGGAAGCGCATTTGAGTACAGAGGCCTGAGTATGGGGATGGGTACCACTGGCTGAGTAGGAAAG      1236

GGGAAGACCAGGTGGCTCCATGCCTTTCCCCAGGTTCTGGAGATGAGCATTGGGGCGCCGGAAGCCCAGCAACGCCTGGCCCTGAGTGAG      1326
                                VALLEUGLUMETSERILEGLYALAPROGLUALAGLNGLNARGLEUALALEUSERGLU

CACCTGGTTACCACTGCCACCTTCTCCATCGGCTCCACTGGCCTCGTGGTGTATGACTACCAGCAGGTGGGTATGCCAGACCTCCTGACC      1416
HISLEUVALTHRTHRALATHRPHESERILEGLYSERTHRGLYLEUVALTYRASPTYRGLNGLN

TGGACCAATGACAACTGGGCTCTGCTAGAGCGCCCAGCTGGCCACTTTCATTCCACATCCATCTCTCCTCTCAGACTTTTTGCTGAGC      1506

CCAGATTCTAGTAGTCTCCCGTGCCCAACCTAGAGGGAGGTGGCTAAGGACCTGGGTCAGGGAGAGGCAGGGCAGGACCCCGAATGATC      1596

TCCAGCATTCTGTGCCTAGCTGCTGATCGCCTACAAGCCAGCCCCTGGCACCTGCTGCTACATCATGAAGATAGCTCCAGAGAGCATCCCC      1687
                                LEULEUILEALATYRLYSPROALAPROGLYTHRCYSCYSTYRILEMETLYSILEALAPROGLUSERILEPRO
```

FIG.10C

```
AGTCTTGAGGCTCTCACTAGAAAAGTCCACAACTTCCAGGTGTGTGTGTGTGGGTGAAAAGAGTGGGCTGTCTCCCTCCCAGGCTGCTGG      1777
SerLeuGluAlaLeuAsnArgLysValHisAsnPheGln

 A          *
AGGAGTGTCCGAATGGTGGCTATTTGTCACCTGTAAAGCACTGTTCCTCATTGGCTGCCAGCTGACTGCCCCTCTCCTATTCCCCTGCAC      1867

                                                                                      T
GACTCCTTTCCTTCCCACCCCACTGCCAAGCTGCTGGGCTCAGCTGAGTCCACTCACTACCTGGTGGCTTCTGACTCTAGCACAGCCCCT      1957

CTTTACTGATGAGAAAACTGAGGCTCAGAGAGATTGCCTGATATACCTGAAGTCCCACAATAAGGGCTGCACATGGGATAGAAACTCACT      2047

  G
TCCTACATTCCAGATGGAATGCTCTCTGCAGGCCAAGCCCGCAGTGCCTACGTCTAAGCTGGGCCAGGCAGAGGGGCGAGATGCAGGCTCA      2138
          MetGluCysSerLeuGlnAlaLysProAlaValProThrSerLysLeuGlyGlnAlaGluGlyArgAspAlaGlySer

GCACCCTCCGGAGGGGACCCGGCCTTCCTGGGCATGGCCGTGAACACCCTGTGTGGCGAGGTGCCGCTCTACTACATCTAGGACGCCTCC      2228
AlaProSerGlyGlyAspProAlaPheLeuGlyMetAlaValAsnThrLeuCysGlyGluValProLeuTyrTyrIleEnd

                                                C      A*  T  CG          -
GGTGAGCAGGTGTGATCCCAGGGCCCCTGATCAGCAGCGGAGGAGCGCTGGCCACCTGCCCGGGCTGTGGAGGAGGCTCGCTGACCAGGC      2318
```

FIG.10D

```
C T  G *                                                                    *
TGGGGCGTCCACTGAAGCGGGGTCATCCAGGCAACTCGGGGGAGGGGAAGCTCACAGACCGGTACTTCCCACTCCCCTGAATTCTCTCTG      2408

                          C
TCCATCCTCAACATTCCTTTGCTTCATAGGGTCAGTGGAAGCCCCAACGGAAAGGAAACGCCCCGGGCAAAGGGTCTTTTGCAGCTTTTG      2498

                                        G
CAGACGGGCAAGAAGCTGCTTCTGCCCACACCGCAGGGACAAACCCTGGAGAAATGGGAGCTTGGGGAGAGGATGGGAGTGGGCAGAGGT      2588

  G                                     -
GGCACCCAGGGGCCCGGGAACTCCTGCCACAACAGAATAAAGCAGCCTGATTTGAAAAGCAAAGGGTCTGCTTCTGTCTTCCTGCAGGGC      2678

                    T           **        CG       T
GCAGTCCTCGCTGGCGGGGCCGGCCAAGAAGGGAAGGGCCTTGGGAGAGCAAAGTGGGGTTTCCATTCGCCCTCTGTCCCAGGGCGCTGG      2768

CACTGTCCACCTCGGCGGGGAGAGGGGCTCGCAGGGAGCATCCACGGGCTTT                                            2820
```

FIG.10E

INTERNATIONAL SEARCH REPORT

PCT/US87/02536

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [3]

According to International Patent Classification (IPC) or to both National Classification and IPC

U.S.CL. 435/320; 240.2, 70, 68; 536/27; 530/324
INT. CL. -4- C12P 21/00,21/02;C12N 5/00;C07K 7/10;C07H 15/12

II. FIELDS SEARCHED

Minimum Documentation Searched [4]	
Classification System	Classification Symbols
US	435/320,240.2; 70,68; 536/27; 530/324

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched [5]

III. DOCUMENTS CONSIDERED TO BE RELEVANT [14]

Category *	Citation of Document, [16] with indication, where appropriate, of the relevant passages [17]	Relevant to Claim No. [18]
A,	The Journal of Biological Chemistry, Issued 5 December 1985, Vol. 260, pages 15273, (Whitsett)	1-6,42 & 44
A,	Biochemistry, Issued 1985, Vol. 24, pages 184-190, (Hawgood)	1-6, 42 & 44
A,	The Journal of Biological Chemistry, Issued 5 July 1986, pages 9029, Vol. 261, (Floros)	1-6, 42 &44
A,	The Journal of Biological Chemistry, Vol. 261, Issued 15 January 1986, pages 828-831 (Floros)	1-6,42 & 44
,X	Chemical Abstract, Vol. 105, Issued 1986, abstract no. 94932s, (Whitsett) "Immunologic identification of a pulmonary surfactant-associated protein of molecular weight"	1-6,42 &44

* Special categories of cited documents: [15]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search [2]	Date of Mailing of this International Search Report [2]
19 JANUARY 1988	25 FEB 1988
International Searching Authority [1]	Signature of Authorized Officer [20]
ISA/US	

Form PCT/ISA/210 (second sheet) (May 1986)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

,P,A	US, A,	4,659,805 (Schilling) 21 Apr. 1987	1-6, 42 & 44
A,	US, A,	4,016,258 (Said) 5 Apr. 1977	1-6, 42 & 44

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE [10]

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers . because they relate to subject matter [12] not required to be searched by this Authority, namely:

2. ☐ Claim numbers . because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out [13], specifically:

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING [11]

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-6, 42 and 44 drawn to DNA sequences Vectors, Cell culturing and protein product.

II. Claims 7-30, 39-41, 45, 50, 54 drawn to peptides and the use in Assay.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

Claims 1-6, 42 and 44

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

ATTACHMENT TO FORM PCT/ISA/210
(SUPPLEMENTAL SHEET(2)CONT"D

III. Claims 31-36 drawn to peptide Lipid compositions and there use.

IV. Claims 37, 51-53 drawn to antibodies and methods for Assay using the antibodies.

V. Claims 38, 46-49 drawn to antibodies and methods for Assay using the antibodies.

VI. Claims 43, 57 and 58 drawn to protein and methods of use.

VII. Claims 55 and 56 drawn to methods of delivering peptides.